Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
639 Cards in this Set
- Front
- Back
Treatment of ABPA |
long–term steroids, (daily prednisone x 14 days, then 3–6 month taper)
16 weeks itraconazole or voriconazole |
|
Diagnostic Criteria for ABPA in asthmatics
|
Asthma:
+ SPT to Aspergillus fumigatus IgE>1000 (417 IU/mL) Incr IgG and IgE to A fumigatus Central bronchiectasis peripheral eos (>1000) |
|
Diagnostic criteria for ABPA in CF
|
clinical deterioration not due to other causes
total serum IgE>1200 ng/mL (500 IU/mL) + SPT to Aspergillus fumigatus Incr IgG and IgE to A fumigatus fixed chest film abnl (infiltrates, mucusplug) |
|
Types of fungal sinusitis
|
acute/fulminant (invasive)
chronic/indolent (invasive) fungus ball allergic fungal sinusitis (most common) |
|
Causative fungi for allergic fungal sinusitis
|
Bipolaris
Curvularia Alternaria Rhizopus Dreschslera Helminthosporum Fusarium Aspergillus |
|
CT findings for allergic fungal sinusitis
|
hyperattenuation
heterogenous opacification calcification |
|
Lab findings for allergic fungal sinusitis
|
Gross: allergic mucin (thick, viscous, tan/brown colored)
Histo: branching noninvasive fungal hyphae, eos in sheets, CHarcot leyden crustals Lab: Incr IgE, fungal IgG, positive fungal SPT |
|
Treatment for allergic fungal sinusitis
|
Endoscopic sinus surgery
nasal saline irrigations oral steroids (usu just before surgery) Topical nasal steroids Immunotherapy–controversial – antifungals don't help |
|
Allergic fungal sinusitis sx (acute and chronic
|
Acute; F, nasal congestion, acute facial pain, headache, diplopia, anosmia acute
Chronic: vision changes/loss, proptosis, sinus tenderness to palpation, malaise, fatigue |
|
Allergic fungal sinusitis diagnositc criteria
|
Type I hypersensitivity to fungi (SPT or IgE)
Nasal polyposis Positive fungal stain of sinus contents Histo: eo rich mucin and fungal elements with no invasion of resp mucosa |
|
Lung disease by TH1 v. TH2
|
Th1:
CD8: HP, COPD CD4: granulomatous (TB, sarcoid, berylliosis) TH2: asthma, ABPA, pulm eosinophilia, HIV, Graves |
|
Hypersensitivity pneumonitis by type (symptoms for Acute)
|
explosive reps sx
non productive cough fever takes 4–6 hours spontaneous recovery HRCT: normal/fleeting ground glass opacities |
|
Hypersensitivity pneumonitis by type (symptoms for Subacute)
|
Progressive
Slow onset productive cough no systemic sx HRCT: diffuse micronodules, air trapping, mild fibrosis |
|
Hypersensitivity pneumonitis by type (symptoms for Chronic)
|
No explosive sx
no fever Fibrotic lung Anorexia/weight loss Permanent damage likely HRCT: groudn glass opacities, emphysema, honeycoming, parenchymal micronodules |
|
Hypersensitivity pneumonitis diagnostic criteria
|
Presence of typical sx
evidence of exposure (history and + IgG0 + radiograph or HRCT BAL lymphocytosis >20% (low CD4/8 ratio<1) Sx on reexposure Can also see bibasilar dry rales, decr DLCO, decr PaO2 with exercise |
|
Hypersensitivity Pneumonitis: Faenia rectivirgula
|
Farmer's lung (moldy hay/compost)
|
|
Hypersensitivity Pneumonitis: Micropolyspora faeni
|
Farmer's lung (moldy hay/compost)
|
|
Hypersensitivity Pneumonitis: Thermoactinomyses vulgaris
|
Bagassosis (modly sugar cane)
|
|
Hypersensitivity Pneumonitis: thermoactinomyces sacchari
|
ventilation penumonitis (humidfier and A/c)
|
|
Hypersensitivity Pneumonitis: Naegleria gruberi
|
ventilation pneumonitis (humidifier and A/C)
|
|
Hypersensitivity Pneumonitis: Acanthamoeba
|
Ventilation pneumonitis (humidifier, and A/C0
|
|
Hypersensitivity Pneumonitis: Bacillus cerus
|
Humidifier's lung (cool mist humidifier)
|
|
Hypersensitivity Pneumonitis: Kelbsiella oxytoca
|
Cool mist humidifier
|
|
Hypersensitivity Pneumonitis: Mycobacterium avium intracellulare
|
hot tub lung
|
|
Hypersensitivity Pneumonitis: aspergillus
|
Malt worker's lung (malt, tobacco and soy)
|
|
Hypersensitivity Pneumonitis: penicillium casei
|
Cheese worker's lung (moldy cheese)
|
|
Hypersensitivity Pneumonitis: penicillium roqueforti
|
Cheese worker's lung (modly cheese)
|
|
Hypersensitivity Pneumonitis: Pseudomonas
|
Machine operator's lung
|
|
Hypersensitivity Pneumonitis: Acinetobacter
|
Machine operator's lung
|
|
Hypersensitivity Pneumonitis: Mycobacter
|
Machine operator's lung
|
|
Hypersensitivity Pneumonitis: Avian proteins
|
Bird fancier's lung
|
|
Hypersensitivity Pneumonitis: aspergillus
|
Bird fancier's lung
|
|
Hypersensitivity Pneumonitis: Bacillus subtilis
|
Detergent worker's lung
|
|
Hypersensitivity Pneumonitis: Alternaria
|
Woodworker's lung
|
|
Hypersensitivity Pneumonitis: STachybotrys
|
winegrowe's lung
|
|
Hypersensitivity Pneumonitis: aureobasidium
|
air–conditioner lung
|
|
Hypersensitivity Pneumonitis: trichosporum cutaneum
|
Summer–type HP (Japan0
|
|
Hypersensitivity Pneumonitis: Pzizia
|
El nino lung
|
|
Hypersensitivity Pneumonitis: Candida albicans
|
Saxophonist's lung
|
|
Hypersensitivity Pneumonitis: epicoccum nigricans
|
basement shower lung
|
|
Hypersensitivity Pneumonitis: sitophilus
|
Wheat weevil lung
|
|
Hypersensitivity Pneumonitis: toluene/ toleuene diisocyanate
|
chemical worker's lung
|
|
Hypersensitivity Pneumonitis: phthalic acid
|
epoxy resin worker's lung
|
|
Hypersensitivity Pneumonitis: trimellitic anhydride
|
plastic worker's lung
|
|
Lab findings in Hypersensitivity pneumonitisi (BAL, lung bx, PFT)
|
BAL: incr CD8, lymph.20%, incr neut, eos, >1% mast, incr IgG/A/M, incr hyaluronic acid
Bx: noncaseating granulomas, mononuclear cell ifniltrates of alveolar walls, foamy histiocytes, giant cells, peribronchiolar fibrosis PFT, 4–6 hrs exposure ––> decr FEV1, FVC, DLCO |
|
Diff'l Dx for hypersensitivity pneumonitis
|
Organic Dust toxic syndrome
Fire–eater's lung Humidifier fever Silo unloader's disease byssinosis histiocytosis usual interstitial pneumonia occasional interstitial lung disease |
|
What is organic dust toxic syndrome
aka sx epi |
aka pulmonary mycotoxicosis
noninfectious febrile illness in workers after dust exposure (contaminated by bact/fung spores) 30–50 times more common than HP young, usually in summer complete recovery |
|
What is fire–eater's lung
|
choking, cough, resp sx from aspiration of flammable petrochemicals used in fire eating
fever and pleuritic chest pain |
|
Humidifier fever
|
toxic alveolitis, recirculated water with ednotoxin
chest tightness 4–8 hrs after exposure |
|
Silo unloader's disease is due to _____
|
acute exposure to NO2 ––> asphyxia
|
|
Byssinosis due to
|
inhalation of cotton, flax, hemp
bronchoconstriction on first day, improves with time |
|
Occasional interstitial lung disease is usually due to
|
flock or nylon
lifeguarding at pool (endotoxin may be cause) |
|
Drugs that cause Hypersensitivity pneumonitis
|
A Boy Came From a Good Home to Make Nice Purple Sweets
Amiodarone, Beta blockers, Chlorambucil/clozapine/cyclosporine Fluoxetine, Gold Heroin/HMG Co–A reductase inhibitors Methotrexate, minocycline Nitrofurantoin Procarbazine Sulfsalazine |
|
Hypersensitivity pneumonitisi
|
Avoidance of offending agent
Glucocorticoids if severe |
|
Usual Interstitial pneumonitis
aka sx imaging Tx |
aka idiopathic pulmonary fibrosis
most common SOB, nonproductive cough X–ray: diffuse interstitial infiltrates CT: honeycombing PFT: restrictive, low DLCO Tx: steroids, txpt |
|
Acute interstitial pneumonitis
aka features |
aka Hamman–Rich syndrome
– diffuse alveolar damage, fever, severe SOB over 1 day, flu–like sx, rapid resp decomp |
|
Nonspecific interstitial pneumonia
|
uncommon ILD (dx of exclusion)
good prognosis |
|
COPD staging
|
GOLD criteria
mild = FEV1>80% (gold1) mod = 50–80 (gold 2) severe 30–50 (gold 3) <30, <50% normal with chronic resp failure (gold4) |
|
Airway inflmmation in COPD due to
|
neutrophisl and macrophages (release matrix degrading enzymes)
Nicotine (inhibits tissue inhibitors of matrix metalloproteinases (TIMPs)) Sputum eosinophils (marker of viral exac) |
|
Centrilobular v panlobular emphysema
|
upper v lower lobes
cigarette smoke v. alpha1 antitrypsin deficiency |
|
COPD treatment
|
short/long acting anticholinergics
LABA (in isolation) ICS only for moderate/severe COPD |
|
Allergenic proteins for main allergens
|
milk – casein/whey
egg – ovalbumin, ovomucoid peanut – vicilin, conglutin, glycinin fish – parvalbumin shellfish – tropomysin |
|
oral allergy syndrome: betv1 (birch) –>
|
apple, peach Mald1
|
|
What is Heiner's syndrome?
|
Food hypersensitivity of unknown immuen mech
recurrent pneumonia, pulm infiltrates, hemosiderosis, Fe def anemia, FTT Dx: hx, peripheral eos, milk precipitins, lung bx, elimination diet |
|
Dermatitis herpetiformis is associated with ____ disease
|
Celiac.
pts are gluten sensitive |
|
Examples of nonimmunologic anaphylaxis
|
Vancomycin
Opiates Radiocontrast media Cold urticaria (causes mast cell /basophil mediator release in absence of IgE) |
|
Biphasic reaction
– timing –frequency – recommended observation time |
– usu several hours, as late as 72 h
– 20% of episodes – 8 hrs is sufficient (24 has been advocated, we do 4) |
|
Drugs that interfere with correcting the hypotension associated with anaphylaxis
|
– Beta–blockers (blunt epi effect, interfere c normal compensatory tachycardia)
– ACEIs (blocks ATI –> ATII, blocks enzyme that destroys kinins) – ARBs (no data) – Tricyclic (exaggerate response to epi by blocking reuptake) – MAOIs (prevent degradation of epi) |
|
Anaphylaxis in mastocytosis versus other forms
|
Total/mature >20 = mastocytosis
Total/mature <10 = other cause |
|
Lab findings in anaphylaxis
|
histamine: rise by 5 min, elevated only 30–60m
urinary histamine: elevated 24h serum tryptase: 15–180 min (peaks 60–90 min) Platelet activating factor |
|
Pretreatment for radiocontrast, cold, fluorescein related anaphylaxis
|
– 50 mg prednisone 13, 7, 1h before procedure
– 50 mg benadryl 1h before – use low osmolar contrast – decreases risk of reaction to <1% |
|
Role of H1 in anaphylaxis
|
– coronary artery constriction
– bronchoconstriction – systemic vasodilation – incr capillary permeability – tachycardia – pruritis – rhinorrhea |
|
Role of H2 in anaphylaxis
|
– coronary artery vasodilation
– incr force of contractions – incr capillary permeability – increase mucus secretion |
|
Role of H3 in anaphylaxis
|
Autonomic receptor downregulator
|
|
Perioperative anaphylaxis usually due to...
|
neuromuscular blocking agents
hypotonic induction agents (barbiturates) antibiotics opioids latex colloids |
|
Natural Rubber latex
– number of proteins – Health care workers react to ____ – more common allergens in those with sensitized patients with spina bifida |
– 13 protein allergens
– Hev b 5, 6, 7 (acidic protein; hevein/prohevin; patatin–like) – Hev b 1 (rubber elongation factor) Hev b3 (prenyltransferse) |
|
Natural Rubber latex
– key food associated antigens |
– Hevb2 (beta–1/3 glucosidase) ––> bell pepper, olive
– HevB5 (acidic protein) ––> kiwi, potato, sugar beet – Hev B 6 (hevein, prohevein) ––> avocado, banana, chestnut, sweet pepper – Hevb7 (patatin like protein) ––> potato/tomato – Hevb13 (latex esterase) ––> potato |
|
Constarch powder in latex jobs ________
|
absorbs allergens and sesnitizes by inhalation
|
|
Dipped rubbed products
|
cause most reactions b/c heat vulcanized at lower temperatures with more intact proteins
|
|
Exercise induced anaphylaxis:
Food dependent exercised induced anaphylaxis – timing of events – associated foods – two subtypes – management |
– sx after physical activity
– food min/hrs prior to exercise ––> anaphylaxis – crustaceans, cephalopods, celery, grapes, chicken, wheat, buckwheat, tomato, dairy, mushrooms – some react after any food (rare) some after specific food. – avoid exercise 4–6 h after food, epi |
|
Family apidai – types of insects
|
Honey bee (apis mellifera)
Killer bee (African–European Hybrid bees) Bumblebee (Bombus spp) |
|
Bees (which type)
– female stings – aggressive – sting when provoked – sting in large numbers – loud/slow attack – beeswax nest with numerous combs –subterranean/concealed nest |
– Honeybee
– Killer Bee – Honeybee, Bumblebee (nests) – Killer bee – Bumblebee – Honeybee – Bumblebee |
|
Family vespidae – which insects
|
Subfamily Vespinae
– vespula (yellow jacket) – Dolichovespula arenia (yellow hornet) – Dolichovespula maculata (white–faced hornet) Subfamily Polistinae – Posistes (paper wasp) |
|
Which vespid
– multiliayer paper nests of masticated wood – nes of single layer of combs – dangling legs in flight – aggressive – sting repeatedly – picnic/trashcan – sting for no reason |
– yellow jacket and hornets
– wasp – wasp – yellow jacket – all of them – yellow jacket – yellow jacket |
|
Which vespid?
– aerial nesting – nests in concealed locations (underground, decaying logs) – sensitivity to vibrations – responsible for most human stings |
– yellow hornets
– yellow jackets – hornets – yellow jackets |
|
Family formicidae
– features – location –nests |
Solenopsis invicta (imported fire ant)
– anchor by mandibles and pivot to give multiple stings and sterile pustule – southeastern US – large subterranean nests |
|
Rates of reactions
– rates of death |
3% adult, 1% children
30–50 fatal stings/year – half with no prior history |
|
Testing for venom IT
|
– intradermal (0.001–0.01 mcg/mL in 10 fold increments)
– conc >1 mcg/ml venom ––> irritant effects – SPT if severe anaphylaxis hx – if negative skin test, in vitro before saying not necessary – sting challenge (gold standard for efficacy of VIT) |
|
Skin test sensitivity in venom testing does/does not correlate with degree of sting reaction
|
does not
|
|
If severe hypothension after hymenoptera sting, do this test...
|
Baseline serum tryptase level
|
|
Management (testing, venom IT) based on rxn:
– No reaction – Large local – urticaria/angioedema – anaphylaxis |
– (1–3% risk systemic reaction)
– (5–10% risk), no SPT/IgE, no VIT – SPT/IgE. If positive ––> child 10% risk, no VIT. If adult 20% risk , VIT. – SPT/IgE. If positive ––> child 40% risk adult 60% risk ––> VIT. If neg ––> repeat testing |
|
Safety of VIT and Efficacy
|
– 50% have large local reactions
– 5–15% have systemic sx during buildup – <5% require epi – 75–95% efficacy |
|
Dosing for venom IT
|
Single: main 100 mcg venom, up to 200 if IT fails
Mixed: 300 mcg maint Imported fire ant = whole body extract – maint dose of 0.5 ml of 1:10 to 1:200 wt/vol extract monthly |
|
Types of biting insects that cause allergies
|
Kissing Bug (triatoma) – nocturnal painless bite
Mosquito (culicidae) – anaphylaxis rare Horsefly/Deerfly (tabanidae) – large blood sucking flies with painful bite Asian Lady Beetle (Harmonia axyridis) – sensitized individuals sometimes have rhinitis, urticaria, asthma sx with bites |
|
Gell–Coombs classification of drug reactions
|
Type I: anaphylaxis
Type II: Antibody dependent cytotoxic reactions Type III: immune complex reactions Type IV: Cell mediated or delayed hypersensitivity reactions |
|
Sub classification of type IV reactions (cytokines, cells, clinical manifestations)
|
IVa: Th1 cytokines, IFNg; monocytes; eczema
IVb: Th2 cytokines, IL–4//5; eosinophils; maculopapular/bullous IVc: CTL (perforin, granzyme); CD4/CD8; maculopapular/bullous to pustular c incr CD8 T IVd: T cell and IL–8; PMNs; pustular |
|
HLA–DR3 associated with increased reactions to ____
|
insulin, gold, penicillamine
|
|
HLA–B5701 associated with reactions to
|
abacavir
|
|
PCN testing to...
|
Major determinants = benzylpencilloyl polylysine (Prepen)
Minor determinants = PCN G, pnicilloate, penilloate Ampicillin/amoxicillin (3–25 mg/ml) |
|
% of PCN allergy due to major determinant
|
80%
|
|
NPV and PPV of PCN drug testing
|
NPV 97% to rule out anaphylaxis
PPV is 60% |
|
Aztreoname cross reacts with _____
|
ceftazidime
|
|
Amoxicillin while EBV –––>?
|
80% have a rash
|
|
__% of pts have a delayed maculopapular rash with amp/amox which _______ IgE mediated
|
10%
is not |
|
PCN cross reactivity
|
moderate with carabpenems (impipenem, meropenem) if positive skin testing
rare with PCN (2%) |
|
Which generation cephalosporin causes more allergic reactions
|
first and second generation
|
|
Typical sulfa reaction
– mechanism – common in this disease – type I reactions are due to ____ – cross reactivity |
Delayed maculopapular rash
– T cell mediated – common in HIv (40–70%) – N4 sulfonamidoyl hapten = major determinant. rare – little cross reactivity between sulfonamid abx and sulfonamide nonabx (furosemide) |
|
Pseudoallergic reactions
– mechanism – examples – risk factors – how to prevent |
Anaphylactoid reactions
– non IgE mediated. Basophil/mast activation – radiocontrast dye, ASA, NSAIDS, opiates – women, asthma/atopy, cardiovascular hx, prior hx of reaction – decrese risk by using lower ionic contrast media and premed with steroids/antihistamines (doesn't work with true anaphylaxis) |
|
Blistering drug reactions
– difference between SJS and TEN – steroids? – High risk triggers – mechanism of action – treatment |
– SJS = <10% epidermal detachment (often confluent purpuric macules, systemic sx, fever, organ involvement – eye/liver/kidney/lung). TEN = >30% involvement
– steroids helpful in SJS, contraindicated in TEN – PCN, sulfonamides, anticonvulsants, NSAIDs, allopurinol – Fas/FasL mediated apoptosis of epidermal cells + CTL activation and perforin release –supportive. IVIG can help by Fas–blocking abs |
|
Vancomycin and Red–man syndrome
– sx – mechanism – treatment – can also cause ____ (other triggers: ____) |
– flushing, erythema, pruritis
– direct activation of mast cells – decrease infusion rate, premed with antihistamines, stop concurrent narcotics – linear IgA bullous dermatitis (tense blisters). Can occur with captopril, furosemide, lithium, bactrim |
|
ACEI Reactions
– common sx – frequency – mechanism – frequent in ___ race – resolution |
– cough (20%)
– angioedema: usually in first week, but 30% present months/yrs later – due to ACEIs interfering with bradykinin degradation so antihistamines don't help – more common in African Americans – can have intermittent episodes when switched to another antihypertensive |
|
DRESS
– common causes – sx – timing/course – treatment |
Drug Rash with Eosinophilia and Systemic symptoms
– anticonvulsants, sulfonamides, allopurinol, minocycline – fever, lymphadenopathy, hepatitis, facial edema – occurs wks after tx, develops over days and may continue despite stopping drug x weeks – Steroids, if no response, IVIG |
|
Fixed drug eruption
– what is it – common cuases |
– purple–blue macule at same location upon each exposure to a drug (can take any derm manifestation)
– bactrim, phenolphthalein |
|
Local anesthetics (lidocaine, other –caines) are most often associated with ____ reactions and positive skin prick tests do/do not predict actual allergy.
|
Vagal
do not |
|
Perioperative agents and drug reactions
– due to ____ – use of skin testing |
– usually quaternanry ammonium muscle relaxants (sux). Also latex, abx, barbs, propofol.
– skin testing helpful if positive, but predictive value unknown if negative |
|
Insulin allergy
– frequency of insulin antibodies – increased risk with HLA–____ – Allergenicity of preparations = treatment |
– 50%
–DR3 – bovine> porcine> human – most continue insulin treatment. antihistamines or splitting helps. Occ protamine allergy if NPH insulin (switch to nonprotamine). insulin desens is possible (though anaphylaxis rare) |
|
Cytokine release syndrome
– associated with – sx – |
– biologics. Rituximab (anticd20) and muromonab (antiCD3), sirolimus (rapamycin)
– fever, rash, wheeze, capillary leak syndrome, meningoencephalopathy, GI sx, abnormal LFTs, uric acid, LDH, IL–6, TNFa – |
|
Sx associated with interferon therapy
|
flu sx, urticaria, dermatitis, vasculitis, ITP, autoimmunity, depression
|
|
Common reaction with these drugs
TNF inhibitors Etanercept Epoetin Alteplase and tPA anti–TNF drugs (infiliximab, etanercept) Cetuximab |
– serum sickness
– injection site / local reactions – pure red cell aplasia – anaphylactoid reactions – disseminated mycobacterial infxn or TB (annual PPD) – alpha–gal |
|
Common causes for drug induced cytopenias
– anemia – thrombocytopenia |
– quinidine, methyldopa, PCN
– quinidine, propylthiouracil, gold, sulfonamides, vancomycin, heparin |
|
Pulm drug hypersensitivity
– sx – triggers |
– cough, migratory infiltrates, peripheral eosinophilia, pumonary fibrosis
– bleomycin, methotrexate, nitrofurantoin (also pleural effusion or interstitial penumonitis/fibrosis), NSAIDS (eosinophilic pneumonia) |
|
Serum sickness
– triggers – sx – occurs in antigen/antibody excess – tx |
PCN, sulfonamides, phenytoin
– fever, erythema multiforme or urticaria, arthralgias, lymphadenopathy – antigen excess – stop the med, steroids, antihistamines (NO DESENSITIZATION) |
|
Drug Induced cutaneous lupus
– associated with ___ abs – rash appearance – common triggers – differs from drug–induced lupus (systemic) which has ___ abs and caused by ____ drugs |
anti–Ro (SSA)
photodistributed erythema/scalyannular plaques weeks after starting drug HCTZ, CCBs, ACEIs, antifungals – antihistone, procainamide, hydralazine, phenytoin, isoniazid |
|
Chemtheropeutics and the reaction type:
Platins (cisplatin/carboplatin/ oxiplaten) Taxanes (pacilitaxel, docetaxel) asparaginase |
– anaphylaxis (desens works)
– anaphylactoid (treat/prevent with steroids/antiH) – either (but some only react to asparginase from E coli) |
|
contraindications to drug desensitzation
|
– blistering skin reactions (TEN/SJS)
– immune complex mediated reactions (serum sickness) – DRESS – hepatitis –hemolytic anemia – nephritis |
|
Chronic urticaria lasts ___ weeks
|
6
|
|
Cold urticaria syndromes that have a negative ice cube test
|
Cold induced cholinergic urticaria
Systemic cold urticaria Cold dependent dermatographism |
|
cholinergic urticaria
– aka – trigger – apperance – tests – can present similar to ___ |
– generalized heat urticaria
– elevation of body temp (heat/exercise, stress, spicyfoods) – small punctate wheals – intradermal methacholine, exercise challenge, hot water bath – exercised induced anaphylaxis b/c can p/w hypoTN. EIA don't react to passive heating |
|
Aquagenic urticaria
– trigger – test |
– wheals from contact with water, indpdt of temp, salinity important
– 35 degree water compress x 30 min to upper body |
|
Delayed pressure urticaria
– trigger – test |
–trigger sx 30 min to 12 h after pressure
– sling with 10–15 lb weight x 15 min and pt watches for response x 4–24 h |
|
Urticaria treatment
– first line –second line – third line |
1: antihistamine
2: 2nd gen antihistamine, H2 blockers, doxepin, singulair, steroids if refractory??? 3: cyclosporine, tacrolimus, methotrexate, sulfsalazine, dapsone, hydroxychloroquine, omalizumab, colchicine, IVIG |
|
Hypocomplementemic Urticarial Vasculitis syndrome
– sx – lab |
urticaria + hypocomlemetemia with arthralgias/arthritis, obstructive lung disease, glomerulonephritis, uveitis, angioedema, recurrent abd pain
– low C3, C4, C1q, antiC1q abs, ESR |
|
Urticarial vasculitis
– sx –labs –histo |
– lesions are less pruritic and more painful/burning. Last > 24h with residual purpura/hyperpigmentation
– ESR, arthralgias, myalgias, fever, leukocytosis – histopath leukocytoclassi and vessel wall damage |
|
Patch testing timing
|
Place pathces on day 1, read and remove on day 3, read again on day 5
|
|
Patch test scoring:
|
extreme rxn: confluent vesicles/bullae, ulcer
strong: microvesicles/erythema in 50%+ weak: erythema and edema that is palpable doubtful – erythema irritant reaction: mild glazed appearnace, mod: follicular/pustular, extreme: ulcerative |
|
Allergic v irritant contact dermatitis
|
Allergic – more pruritic, crescendo phenomenon, slower to develop
Irritant – more stinging, reaction almost immediate with decrescendo patch testing |
|
Photocontact dermatitis
– photoallergic: triggers requiring prior sensitizaiton – phototoxic: triggers not requiring prior |
requires light and the exposure
– PABA, chlorhexidine, thiourea, NSAIDS, thiazide diuretics, dapsone, sulfonylureas – psoralens, furocoumarins, tar, lime, celery, parsnip, tetracyclines, amiodarone, diuretics, quinine, NSAIDs |
|
Contact urticaria
– types – examples |
IgE dependent ( all the usual suspects) v. IgE indpdt (fragrances, arthropods, jellyfish, coral)
|
|
Ten most common contact allergens
|
nickel sulfate
neomycin myroxylon pereirae (balsam of Peru) fragrance mix thimerosal sodium gold thiosulfate quaternium–15 formaldehyde bacitracin cobalt chloride |
|
Potassium dichromate comes from
|
stainless steel, chrom plating, tanned leather
|
|
Chromates come from
|
textile, leather tanners, wet cement
|
|
Cobal dichloride comes from
|
dental implants, artificial joints, engines/rockets
|
|
Nickel containing material tests
|
Dimethylglyoxime test (pink = positive)
|
|
Poison ivy/oak sumar caused by
– corss reactivity |
urushiol, an oleoresin from sap
– cross reactivity with mango peels |
|
Most common cause of hand eczema in flower workers
|
Alstroemeria (peruvian lily)
|
|
Common causes for contact derm
|
ambrosia (giant/dwarf ragweed)
compositae (chrysanthemums, daisies) liliaceae (tulip, hyacinth, asparagus, garlic) Amarylidaceae (daffodil, narcissus) Primrose (primula) umbeliliferae (carrots, celery, parsnips) urticaceae (nettles) rutaceae (orage, lemon, grapefruit) |
|
Balsam of Peru cross reactivity
|
wide but most common is cinnamon and vanillin
|
|
Preservative agents commonly triggering contact dermatitis that are formaldehyde releasers
|
diazolinidinyl urea
imidazolindinyl urea quaternium–15 DMDM hydantoin Bromonitropropane |
|
Preservative agents commonly triggering contact dermatitis that are not formaldehyde releasers
|
parabens
methylisothiazolinone phenoxyethanol PCMX and or PCMC benzlkonium chloride thimerosol |
|
hair products that cause contact dermatitis
|
cocamidopropul betaine
paraphenylene diamine glycerol thioglycolate |
|
Nails and contact dermatitis
|
ethylacrylate
foramadlehyde based nail resins |
|
Exceipient chemicals that cause allergic contact dermatitis
|
antioxidants,
edta butylen glycol, polyethylene glycol, propylene triethanolamine ethylenediamine vegetable gums chlorocresol, thimerosal benzylalkonium chloride cetrimide lonalin chloramine–T butyl alcohol |
|
Chemical free sunblocks have
|
titanium dioxide and zinc oxide (rare sensitizers)
|
|
Test photoallergic contact dermatits with
|
photo patch testing (patch + UVA (320–400 nm UV light)
|
|
Topical corticosteroids and allergic contact dermatitis
– common causes – common screening agents – when to read patch results |
– Gr A (hydrocortisone), Gr B (triamcinolone), Gr C (betamethasone), Gr D(hydrocortisone 17 butyrate)
– budesonide and tixocortol pivalate 1% – 7 days after application d/t immunosuppression of steroid usually pts only react to 1–2 classes |
|
Common resins causing allergic contact dermatitis
|
epoxy (uncured)
colophony (from pine trees, in makeup, meds) ethylenediamine dihydrochloride ( in creams, nystatin, aminophylline) paraphenylendiamine (henna) topical abx (bacitracin, neomycin) |
|
Allergic contact cheilits
– affects ___ – triggers |
– lips
– dental devices, lipstickes, lip balms, nail polish, cigarette paper, essential oils |
|
Surgical implant dermatitis
– diagnostic cirteria |
– dermatitis (local/general) after implant surgery
– dermatitis persitent and resistant to therapy – positive patch test to metallic component or implant or acryllic glues – resolution of dermatitis after removal of implant |
|
Systemic contact dermatitis
|
generalized rash from systemic administration of drug to which previously had allergic contact dermatitis
aka baboon syndrome b/c indurated erythema in groin area (seen in steroids or benadryl) |
|
This type of vaccine is protective after 1 dose
|
live attenuated
|
|
IVIG/Ig interfere with this type of vaccine
|
live atennuated
|
|
Examples of live vaccines
|
LMNOP and RSV
Live vaccines include MMR Nasal flu Oral Polio Rotavirus Smallpox, Shingles Varicella |
|
Whole cell inactivated vaccines
|
Polio (IPV)
Hepatitis A Rabies |
|
Fractional inactivated vaccines
|
Subunit:
Hep B, trivalent influenza virus vaccine, pertussis, HPV Toxoid: tetanus, diptheria |
|
Polysaccharide inactivated vaccines
|
Pneumococcal (23–valent, pneumovax)
Meningococcal (Menomune) |
|
Contraindications for live attenuated flu vaccine
|
immunocompromised pts
hx of GBS history of recurrent wheeze or severe asthma |
|
Conjugated inactivated vaccines
|
Prevnar (13 serotype)
Meningococcal: Menactra) – immunogenicity improved with conjugation of polysaccharide to protein and is T cell dpdt. |
|
Separation of vaccines
|
– not needed for inactivated vaccines
– 28 days for live vaccines (if not given on same day) |
|
Waiting period btwn administration of passive Ab (IVIG and RBC) and live vaccine
|
tetanus Ig 3 months
IVIG wait 8 months packed RBCs wait 6 months – if given too soon, repeat dose – if live vaccine given, wait >2wks to give product – not a problem with monoclonal antibodies |
|
Vaccines containing egg
|
Influenza
Yellow Fever |
|
Common triggers for IgE mediated reactions to vaccines
|
Gelatin (MMR, VZV, rabies, yellowfever)
Egg (yellow fever, flu – but probably fine) Latex – vials in rubber stoppers Yeast – Hep B vaccine – Japanese encephalitis virus vaccine causes delayed urticaria/angioedema |
|
Unique reactions to vaccines
MMR Tetanus Pertussis Varicella Yellow Fever Smallpox |
Unique side effects from vaccines
– transient rash, thrombocytopenia, late fever – brachial neuritis, arthus reaction – febrile seizures, cyring, hypotonic event – chickenpox like rash – encephalitis – myopericarditis, eczema vaccinatum |
|
Contraindications to vaccines
|
– severe allergic reaction to prior dose
– encephalopathy <7 days after pertussis containing vaccine – history of GBS (flu, meningococcal) – pregnancy and immunosuppression |
|
Etiology of peds v. adult bronchiolitis
|
Peds: RSV, rhino, paraflu, HMPV, influenza
Adult: inhalational injury, mycoplasma, drug, hypersensitivity pneumonitis, connective tissue disease |
|
Independent risk factor for the development of frequent wheezing
|
RSV infection
|
|
SWelling from HAE lasts ____
|
2–4 days
|
|
% of new mutations in HAE (no family hx)
|
15%
|
|
HAE specific therapies for acute attacks
|
C1 INH concentrate (Berinert 20 U/kg IV)
kallikrein inhibitor (ecallantide = Kalbitor 30 SQ) bradykinin receptor antagonist (Icatibant = Firazyr 30 SQ q6 h, max 3 doses/24h) |
|
Long term HAE therapy
|
Attenuated androgens (danazol, stanozolol)
Plasma derived C1 INH (Cinryze, 1000 u IV q3–4d) |
|
Common AEs with attenuated androgen therapy
|
hepatotoxicity
dysplipidemia masculinization headaches |
|
Short term prophylaxis for HAE
– when to use – what meds |
– before oral/gen surg procedures
– androgens (high dose, 3–5 d prior), C1 esterase inhibitor (1–2 h prior) |
|
OB/GYN considerations in HAE
– contraception – pregnancy – Delivery |
– avoid estrogens. Progestin ok
– androgens contraind, C1 inh tx preferred – plasma derived c1inh tx advised before c/s, forceps, vacuum |
|
Warning signs for PIDs
|
>=4 new otitis in 1 year
>= 2 serious sinusitis in 1 year >= 2 mo on abx with little effect >= 2 pneumonias in 1 year failure of infant to gain weight / grow recurrent deep skin or organ abscesses persistent thrush in mouth or skin fungal need for IV abx to clear infxns >= 2 deep seated infxn (including septicemia FMHx of PID |
|
Which HAE medication has a black box warning for anaphylaxi
|
Kalbitor (ecallantide)
|
|
Common organisms associated with antibody deficiency
|
Viruses: enterovirus (XLA)
Bacteria: S pneumo, H flu, Moraxella, Pseudomonas Protozoa: Giardia – no mycobac, fungi |
|
Common organisms associated with combined immunodeficiencies
|
Viruses: all, esp CMV, RSV, EBV
Bacteria: Salmonella, Listeria, enteric Mycobacteria: nonTB (incl BCG) Fungi: Candida, Aspergillus, Cryptococcus, Histoplasma capsulatum Protozoa: Pneumocystis jiroveci, Toxplasma, Cryptosporidium parvum |
|
Common organisms associated with phagocyte defects
|
BActeria: S aureus, burkholderia cepacia, nocardia, Serratia
Mycobacteria: NonTB (incl BCG) Fungi: candida, aspergillus – no viruses, protozoa |
|
Common organisms associated with complement deficiency
|
Neisseria meningitidis
– no viruses, mycobac, fungi, protozoa |
|
Initial workup for PID:
Quantitative assessment |
Humoral: flow (cd 19/20), Igs
Cellular: CBC/D, HIV, flow (CD3/4/8/16/56) Phagocytic: ANC, flow (CD11, 18, 15a) Complement: C3/4 |
|
Initial workup for PID
qualitative or functional assessment |
Humoral: hemagglutinin titers, dep/tet/polysaccharide titers
Cell: DTH response, Nk assay, mitogen/antigen stim, cytokine production, cytotoic assays Phagocytic: NBT, Antineutrophil antibodies Comlement: CH50, AH50 |
|
SCID Gene defect based on lymphocyte phenotype:
T– B+ NK– |
IL–2RG
JAK3 PNP (can have +/– NK) |
|
SCID Gene defect based on lymphocyte phenotype:
T– B+ NK+ |
IL–7RA
IL–2RA CD45 CD3 (delta, episilon, zeta) PNP (can have +/– NK) |
|
SCId Gene defect based on lymphocyte phenotype:
T– B– NK+ |
RAG 1/2
Artemis Cemunnos Ligase IV Nijmegen breakage syndrome (NBS1) |
|
SCID Gene defect based on lymphocyte phenotype:
T– B– NK– |
ADA deficiency
|
|
Gene defect based on lymphocyte phenotype:
CD8+ lymphopenia |
MHC class I deficiency (TAP 1/2, tapasin)
ZAP 70 deficiency |
|
Gene defect based on lymphocyte phenotype:
CD4+ lymphopenia |
bare lymphocyte syndrome (MHC Class II deficiency)
LCK deficiency HIV infection |
|
SCID – common gamma chain is involved in these receptor signaling
|
IL–2, IL–4, IL–7, IL–9, IL–15, IL–21
|
|
IL–7Ra and CD45 and CD3 are specific for only ____ cell development so phenotype is ____
|
T cell
B+ Nk+ |
|
Jak3 is a signaling protein of ____ so it has the same phenotype
|
Common gamma chain (IL–2Rg)
|
|
RAG 1/2 are involved in ____ therefore phenotype is _____
|
only VDR rearrangement of T and B cell receptor formation
Nk+ |
|
Omenn's syndrome
– sx – genes |
Sx: erythroderma, incr lymphoid tissues, alopecia, recurrent infections, eosinophilia, high IgE
Genes: RAG 1/2, IL–7RA, ADA, ARtemis, RNA component of RNASe mitochondrial RNA |
|
ADA deficiency
– distinct clinical features |
– skeletal abnormalities
– rachitic rosary rib cage – abnormal iliac bone – deafness |
|
PNP deficiency
– distinct clinical features |
lymphoreticular disease
autoimmune disease |
|
Reticular dysgenesis
– distinct clinical features – gene abnormality |
– severe neutropenia, sensorineural deafness, SCID features
– Adenylate kinase 2 (AK2) |
|
X linked SCID
|
common gamma chain (IL2Rg)
|
|
Radiosensitive SCID
|
ARtemis
Cernunnos Ligase IV Nijmegen breakage syndrome |
|
Artemis SCId
– distinct clinical features |
diarrhea, cadidiasis
affects athebascan–speaking navajo/apache |
|
Cemunnos
– distinct clinical features |
devtal delay, growht failure, bird like facies, microcephaly
|
|
LIgase IV
– distinct clinical features |
– developmental delay, FTT, bird like facies, microcephaly, photosensitivity, pancytopenia, malignancy
|
|
Nijmegen breakage sydrome
– clinical features |
micocephaly, recurrent infections, bird like facies, devtal delay, lymphoma, short stature, clinodactyly, syndactyly, radiosensitive
|
|
Nijmegen breakage sydrome
–lab features |
– class switch recombination defect (decr CD4/8, decr prolif, can have hypogam, elevated igM, defect in specific ab response, absence of HAssel's corpuscles on thymic bx)
|
|
Ataxia Telangiectasia
– clinical findings |
– progressive neuronal loss (starts ~2)
– Oculomotor apraxia, dysarthria, choreoathetosis – telangiectasia – sterility – leukemia/lymphoma risk – recurrent sinopulmonary infections |
|
Ataxia Telangiectasia
– lab findings |
– lymphopenia of naive T cells (CD45 RA)
– poor mitogen response – class switch defect: can have hypogam and poor fxnal AB – IgA deficiency (80%) – elevated AFP and decreased CSA – Mutation in the ATM gene |
|
Function of ATM
|
ataxia–telangiectasia mutated
– PI3 kinase responsible for DNA ds break repair – mutations lead to radiosensitivity |
|
Ataxia Telangiectasia
|
– treatment
– prophylactic antibiotics – IVIG – chemotherapy – avoid radiation from imaging |
|
Chronic Mucocutaneous Candidiasis (CMC)
Autoimune polyglandular syndrome (APS–1) Autoimmune polyendocrinopathy – candidiasis – ectodermal dystrophy (APECED) – clinical features |
– recurrent noninvasive thrush
– candidal dermatitis – dystrophic nails, enamel hypoplasia – endocrinopathies (hypoparathyroid (most common), hypoadrenalism, DM) – pernicious anemia – vitiligo, alopecia – hepatitis |
|
Chronic Mucocutaneous Candidiasis (CMC)
Autoimune polyglandular syndrome (APS–1) Autoimmune polyendocrinopathy – candidiasis – ectodermal dystrophy (APECED) –lab features – mutation |
– decr mitogen prolif and antigen prolif
– some IgA deficiency – autosomal recessive, AIRE gene |
|
Chronic Mucocutaneous Candidiasis (CMC)
Autoimune polyglandular syndrome (APS–1) Autoimmune polyendocrinopathy – candidiasis – ectodermal dystrophy (APECED) –treatment |
– antifungal
– autoimmune disease |
|
CD40/CD40L deficiency
– aka – gene mutations inheritance – clinical features |
HyperIgM1 = CD40L def; Hyper IgM3 = CD40 def
– CD40L (CD154, TNFS5) = X linked – CD40 = aut rec – opportunistic infection, fungal, bacterial, viral – autoimmune hemolytic anemia, neutropenia |
|
CD40/CD40L deficiency
– lab findings |
Class switch defect:
decr IgG/A/E variable high/normal IgM neutropenia absent germinal centers |
|
CD40/CD40L deficiency
– treatment |
IVIG
PCP prophylaxis GCSF transplant (CD40L def) |
|
DiGeorge syndrome
– clinical features |
– cellular immune deficiency ( infxn, no thymus)
– hypocalcemia/parathyroid def (tetany/seizures) – congenital heart disease (TOF, interrupted AA) – low set post rotated ears, short filtrum, micrognathia – devtal delay – B cell lymphoma – autoimmune disease |
|
DiGeorge syndrome
– lab features |
– complete: naive T <50/mm3 with no mit prolif
– partial: decr naive T cell, usually normal mit proilf – can have low Ig if severe T cell defect – kidney agenesis (on ultrasound) – autoimmune antibodies, TUPLE1 (FISH) – low copy repeat and TBX1 |
|
Digeorge syndrome
– mutation – mnemonic |
22 q 11.2 deletion (90%)
10p13–14 del (renal/gu defects) CATCH 22:Cardiac defects abnormal facies thymic hypoplasia cleft palate chromosome 22 |
|
Digeorge syndrome
– treatment |
– thymus txpt
– IVIG – abx prophylaxis – live vaccines if normal prolif – surgery for congenital defects – neuropsychiatric therapy |
|
NEMO deficiency (null mutation)
– aka – clinical features |
X linked inconginentia pigmenti
males: lethal females: scarring, alopecia, hypodontia |
|
NEMO deficiency (hypomorphic mutation)
– aka – clinical features |
X linked anyhdrotic ectodermal dysplasia with immunodeficiency
Male: – decr sweat, hyperthermia, hypotrichosis, hypodontia, conical incisors, nail abnormality – severe bact infxn, OIs incl mycobacteria Female: usu normal |
|
NEMO deficiency
– lab findings |
hypogam and poor polysaccharide resonse (defect in CD40 activation pathway)
TLR defect (NFkB is central in TLR activation) decr Nk cytotoxicity normal T cell count and function |
|
Nemo deficiency
– treatment |
– IVIG, interferon gamma
– HSCT under investigation |
|
LZ–NEMO deficiency
– clinical features – distinct lab features – therapy |
Clin: normal ectoderm, MAI infxn, disseminated BCG
Lab: impaired production of IL–12 and IFNg in response to CD40L Tx: treat mycobacteria. Antimycobacterial prophylaxis in some pts |
|
Hyper IgE syndrome (STAT–3)
– clinical features |
Triad: (1) Recurrent skin and lung infections (absceses, mucocut candidiasis, eosinophilic pustular folliculitis)
(2) Severe Eczema (3) Elevated IgE – Facies: coarse, prominent mandible, hypertelorism, broad nose, skeletal abnl, retained teeth, scoliosis – hyperextensible, aortic aneurysms |
|
Hyper IgE syndrome (STAT–3)
– lab features – inheritance – treatment |
– IgE>2000, eosinophilia, normal IgM, Th17 levels decr
– aut dom – prophylactic abx, IVIG |
|
Chracteristic infections in Hyper IgE syndrome
|
– S aureus
– S pneumo – H flu – Candida secondary infection – pseudomonas – aspergillus |
|
Hyper IgE syndrome (DOCK8)
– clinical features – lab features – inheritance |
– viral skin infxn (HPV, HSV, VZV, molluscum)
– mucocut candidiasis – eczema and allergies –risks of malignancies – pneumonias but no pneumatoceles – lab: log IgM, more eos, lymphopenia – aut rec |
|
Hyper IgE syndrome
– how Tyk2 mutation differs from Dock8 – role of Tyk2 |
– similar but also has disseminated BCG and vasculitis
– Tyk2 involves in IL–12 signaling to make IFNg |
|
IPEX
– stands for – clinical findings |
Immune dysregulation, polyendocrinopathy, enteropathy and x linked inheritance
– severe infections – early onset type 1 DM, thyroid dz, autoimmune cytopenia – diarrhea and fTT – coronary artery disease – skin lesions: erythroderma, exoliative dermatitis, eczema, psoriasis like |
|
IPEX
– mutation – lab values |
Foxp3 (not found in all cases, X linked rec)
Lab: – Scope: villous atrophy with lymphocytic infiltrates in small bowel – autoimmune abs – cytopenia, eosinophilia – high IgE, normal IgG, IgM – normal B/T number/fxn, except no T regs |
|
IPEX
– therapy |
– IVIG
– treat autoimmune/endocrine – HSCT – parenteral nutrition |
|
X–linked lymphoproliferative disease (XLP–1)
– clinical features |
– fulminant EBV mononucleosis
– dysgammaglobulinemia, CID with severe infxn – lymphoma: B cell/ Burkitt's, splenomegaly |
|
X–linked lymphoproliferative disease (xLP–1)
– lab findings – mutation |
HLH on BM biopsy (from failure to eliminated EBV infected B cells)
low igG, high IgM low CD4, high CD8, impaired T cell function decr NK cell number and function no NKT cells anemia – mutation in SH2D1a gene for SAP |
|
X–linked lymphoproliferative disease (xLP–1)
– treatment |
IVIG
HSCT chemotherapy for lymphoma |
|
X–linked lymphoproliferative disease (xLP–2)
– mutation – how it differs from XLP1 |
– mutation in XIAP
– colitis – preisposition to hemophagocytic lymphohistiocytosis – incr suscetibility to apoptotic stimuli |
|
Wiskott Aldrich syndrome
– clinical features |
Triad:
(1) Thrombocytopenia + bleeding diathesis (2) Eczema (3 recurrent infections (pyogenic) – risk for autoimmunity and malignancy (eBV lymphoma) |
|
Wiskott Aldrich syndrome
– lab findings – gene mutation, inheritance – treatment |
– Incr IgE/A, decr IgM, normal IgG but impaired fxnal abs
– impaired T cell prolif – decr plt size/function – mutation in WASp (X linked) – HSCT, treat infections, IVIG, splenectomy |
|
Consider antibody deficiencys if patient has ____
|
recurrent sinopulmonary infections
enteroviral infections (XLA) giardiasis autoimmune phenomenon |
|
Transient hypogammaglobulinemia of infancy
– clinical features – lab findings – therapy |
– sinopulm/GI infxn, thrush, mild–mod meningitis, may be asx
– IgG < 2SD persisting older than 6 mo. Usually normal ab responses – no Tx. Occ proph abx rarely IVIG, resolved by 2–4y |
|
Selective IgA deficiency
– mutation – clinical features – lab findings – therapy |
– unkown, some CVID + sIgAD have TACI
– Most asx. Some sinopulm, gi infxn, autoimmune, atopic dz, rare transfusion reactions if they have anti–IgA ab – IgA <7 mg/dL (if >4y old) – proph abx and IVIG if specific ab defect, watch for progression to CVID |
|
Possibly triggers of secondary IgA deficiency
|
Antiepileptics
Sulphasalazine ecaptopril thryroxin |
|
Diseases that can have selective IgA def
|
Ataxia telangiectasia
IgG2 subclass def CMC |
|
Specific antibody deficiency
– clinical findings – lab findings – treatment |
– sinopulm infxn allergic rhinitis
– normal Igs, poor polysaccharide response despite pneumovax – prophylactic abx and IVIG, watch for progression to CVID |
|
X linked agammaglobulinemia
– mutation – clinical findings |
– BTK
– sinopulm/GI infxn, atypical bac, enteroviral encephalitis, septic arthritis, lymphoreticular/colorectal malignancies, bronchiectasis |
|
X linked agammaglobulinemia
– lab findings – treatment |
– histo: small/absent lymphoid tissue, no germinal centers
– low IgG (<200), A, M – <2% CD19+ B cells – maturational arrest at the pre–B cell stage – can't use serological assays to diagnose infenction (HIV ELISA) |
|
X linked agammaglobulinemia
– treatment |
– IVIG
– abx prophylactically – live immunizations contraindicated |
|
Autosomal recessive agammaglobulinemia
– mutation, inheritance – clinical findings – lab findings – therapy |
– surrugate light chain (V preB lambda5), mu IgM heavy chain, Iga, Igb, BLNK
– sx same as XLA but can be more severe/earlier onset – low IgG/A/M, low CD19 B cells – tx same as XLA |
|
CVID
– inheritance/mutation – clinical features |
– mostly unknown, ICOS, tACI, BAFF–R, CD19, cD20
– sinopulm/GI infxn, meningitis – bronchiectasisi, BOOP – autoimmune dz, – gi/liver dz granulomatous dz nonhodgkin's lymphoma, gastic carcinoma |
|
CVID
– lab findings treatment |
IgG (<450), low A/M, impaired fxnal abs
variable T cell counts/function – IVIG, treatment, Abx, no live vaccine, pulm hygeine if bronchiectasisi |
|
Good's syndrome
– what is it |
– CVID + thymoma
|
|
Reduced switched memory B cells in CVID associated with _____
|
non infectious complications like hematologic autoimmunity
|
|
Hyper IgM (type 2 and 4)
– clinical features |
– sinopulm and gi infxn
– lymphoid hyperplasia and adenopathy CVID like but with increased autoimmune disease |
|
Hyper IgM type 2 – mutation and inheritance
|
AID deficiency (activation induced cytidine deaminase)
autosomal recessive |
|
Hyper IgM type 4 ( mutation and inheritance)
|
UNG (uracil DNA glycosylase)
autosomal recessive |
|
Hyper IgM type 2 and 4
– lab findings |
– defect in class switch recombination and somatic hypermutation
– no T cell defect – low IGG (<400), A, E, and normall/high IgM – normal T cell function – incr lymph nodes and giant germainl centers |
|
Hyper IgM type 2/4
– treatment |
IVIg
Abx no live vaccines |
|
What are the differences between HIGM 1/3 and HIGM 2/4?
|
T cell defects in 1/3 with absent LN and germinal centers
2/4 are Ab deficiencies with less severe infxn and lymphoid hyperplasia/adenopathy |
|
Phagocytic defects evaluation
CBC NBT MPO Chemotaxis CD18 CD15a |
– LAD 1/2/3, cyclic neutropenia, SCN, AIN, SDS
– CGD – MPO deficiency – SDS, chediak–higashi, LAD, Rac2 mutation – LAD1 – LAD2 |
|
WHIM syndrome
– stands for – clinical features – treatment |
Warts, hypogammaglobulinemia, infections and myelokathexis
– sinopulmonary infxn – papilloma virus infxn – warts with risk of malignant transformation Tx: GSCF, IVIG, wart rx, CXCR4 inhibitor in trial |
|
WHIM syndrome
– lab findings |
neutropenia (ANC 100–500) from retention of mature granulocytes in bone marrow = myelokathexis
ALC 1500 , occ decr mitogen responses IgG low, low CD19 and cD27 (B cells & switched memory b cells) |
|
WHIM syndrome
– molecular defect |
activating mutation in CXCR4 (important for bone marrow homing and trafficking of progenitor cells)
|
|
sEvere congenital neutropenia (SCN)
– clinical findings – treatment |
– early onset severe bacterial infections: omphalitis, URTI/LRTI, oral ulcer, skin/liver absscess, cellulitis, meningitis
– rx: GcSF, HSCT, monitor for myelodysplasia/AML |
|
severe congenital neutropenia
– laboratory findings – molecular defect |
– ANC < 200
– BM: maturation arrest of netrophil precursors at promyelocyte stage – aut rec (HAX1 (Kost mann syndrome) – aut dom Elastase (ELA–2), GCI1, GSCF–R – X linked WASP |
|
Types of phagocytic cell disorders
– Defects in bone marrow production/release |
WHIM
severe congenital neutropenia cyclic netropenia |
|
Cyclic neutropenia
– clinical features – treatment |
– oral ulcers, fever, skin infection, abscesses
– prophylactic ABx, GSCSF |
|
Cyclic neutropienia
– lab findings – molecular defect |
– decr neutrophiles, plts, monos, reticulocytes for 3–6 d in 21 day cycle
– need to get CBC 2–3 /wekk x 6 weeks to diagnose –auto dom: ELA–2 |
|
Types of phagocytic cell disorders
– Defects in adhesion and chemotaxis |
– LAD1
– LAD2 – LAD3 |
|
Types of phagocytic cell disorders
– Defects in leukocyte granula formation – Defects in oxidative killing |
– Chediak Higashi
– CGD |
|
LAD1
– clinical features – treatment |
– recurrent pygoenic infections (impaired pus formation)
– delayed wound healing (delay cord separation) – necrotic skin infections – gigivoperiodontitis – omphalitis Rx: abx rx and rpophylaxis, GCSF, HSCT |
|
LAD1
– lab findings – molecular defect |
– leukocytosis
– decr cd18 on neut (<2% sev, 2–30% mild/mod, 40–60% carrier) – defect ITGB2 ––>defect in CD18 (common chain of b2 integrin family ––> defect in adhesion – CD18 binds LFA1, Mac1 P150,95 (CD 11a, b, c) |
|
LAD2
– clinical features – treatment |
– less evere skin/lung infxn
– no delayed cord separation – impaired but not absent pus formation – devtal delay, microcephaly , short stature Rx: abx proph, fucose supplementation |
|
LAD2
– lab findings – treatment |
– leukocytosis, absence of CD15a
– bombay blood phenotype (hh) – abnormal sequenc of GDP fucose transporter – mutation in FUCT1 ––> no fucosylation ––> no Sialyl–Lewis (CD15) ––> defect in rolling |
|
LAD3
– clinical features – lab findings – mutation |
– same as LAD1 + bleeding diathesis
– leukocytosis, normal cD18, abnl RAP1 gtpase fxn – caldag–ge1 mutation ––> failure of cytokine activation of integrins |
|
Chediak– Higashi
– clinical features |
oculocutaneous albinism
hypopigmented skin/iris/hair recurrent infections bleeding tendency neurologic defects lymphoma like syndrome risk of HLH |
|
CHediak Higashi
–lab findings – mutations |
– enlarged primary granules in neut/eos
– neutropenia, decr chemotais – absent Nk cytotoxicity – evenly distributed larger melanin granules on hair shaft – CHS or LYST mutation |
|
CGD
– clinical features – common organisms |
– ifxn with cat positive organisms
– granuloma formation (GI/GU obstruction) – poor wound healing – autoimmune dz – BAct: S aureus, burkholderia, serratia, nocardia, – Fungi: aspergillus fumigatus/nidulans |
|
CGD
– lab findings – mutation |
abnormal NBT/DHR
mutations in NADPH oxidase system XL: gp91 phox AR: p22, p47, p67 |
|
CGD
– treatment |
bactrim and itraconazole prophylaxis
IFN gamma systemic corticosteroids for granuloma formation HSCT |
|
IRAK4/MyD88 deficiency
– clinical presentation –treatment |
– severe early/onset recurretn pyogenic bacterial infections (pneumococcus, staph)
– menigitis – septicemia – liver abscess – low/absent fever or inflammatory responses – TX: IVIG, proph/rx abx (bactrim and PENV) |
|
IRAK4/ MyD 88 deficiency
– lab findings |
– normal ig levels
– impaired polysaccharide titers – normal B/T cell numbers – dx based on decreased TLR stimulation assay (except TLR 3) b/c defect in TLR signaling to activation of NFkb and AP–1 |
|
IFN gamma/ IL–12/ IL–23 axis
– descrie the axis – results in |
TH1 cels/DC/Nk make IFN g ––> induces IL–12 from DC and macs ––> incr IFNG production. INvolves STAT 1 and 4
Mendelian susceptabilty to mycobacterial disease (MSMD) |
|
Nk cell deficiency associated with
|
HLH
– primary (XLP, familial, chediak higashi, WAS) – secondary (reactive hemophagocytic syndrome) NEMO LAD1 IFN12/IFNg axis HIV infxn Malignancy |
|
Classical NK cell deficiency
– clinical features – lab findings – gene defect |
– recurrent infections with herpes, papilloma virus and mycobacteria –
– decr CD16 flow, decr NK fxn – GATA2/ MCM4 mutation |
|
Functional Nk cell deiciency
– clinical features – lab findings – gene defect |
– recurrent herpes einfections
– normald CD16 but decr NK function – FCRG3A (CD16 mutation = low affinity IgG receptor)) |
|
Complement deficiencies
– inheritance |
All autodomal dominant except properdin = X linked
|
|
Distinguishing complement deficiency versus complement consu,ption
|
Deficiency has normal complement split products while consumption has high complement split products
|
|
Complement deficiency: early (C1q/c1s C2/C4)
– clinical features – infectious organisms – lab findings – gene defect |
– sinopulmonary infxn, autoimmune dz
– S pneumo, H flu (encapsulated org) – low CH50 – none |
|
Complement deficiency: C3
– clinical features – infectious organisms – lab findings – gene defect |
– sever infxn (like ab def), glomeruloneprhtisi
– encapsulated organisms (neisseria) – low CH50, aH50, C3. Also C3 NE and Anti–C3 autoab – defect in C3 |
|
Complement deficiency: MBL
– clinical features – infectious organisms – lab findings – gene defect |
– many asx. Autoimmme, n resp ifxn
– NEisseria – decr MBL – defect in MASP2 |
|
Complement deficiency: late component
– clinical features – infectious organisms – lab findings |
– menigitis arthristis, sepsis,
– c5–7 associated with autoimmunity – Nesseria (menigitidis, gonorrhea) – decr CH50, specific ocmlement, AH50 |
|
Complement deficiency: Altternative pathway
– clinical features – infectious organisms – lab findings |
– factor b/ d/ properdin
– infections – neisseria – low AH50 |
|
Mutations in IFNgR, p40 subunit, IL12 b1, NEMO, STAT1 are susceptible to _____ organisms
|
atypical mycobacteria, salmonella
|
|
HIV 1 v 2
|
HIV 1: more common, virulent/infective
HIV2: confined to West Afria |
|
HIV Viral structure
|
– two identical ssRNA
– enzymes (RT, integrase, protease) packaged in a core of nucleocapsid p24 and outer membrate p17 – host derived lipid bilayer with gp120 and gp41 |
|
Factor H deficiency is associated with _____ diseases
|
Atypical Hemolytic uremic syndrome
HELLP Secondary C3 deficiency Macular degeneration |
|
DAF and CD59 deficiency are associated with ___ diseases
|
Paroxysmal Nocturnal hemoglobunuria (PNH)
|
|
Viral entry requires____
|
Gp120 binds CD4 and CCR5 or CXCR4
co receptor binding ––> conformational change in gp41 ––> entry of viral genome into cytoplasm |
|
HIV coreceptor tropism
– host cells and HIV strain and stage of infection |
CCR5:
– monocytes/macs – M tropic or R5 strain – acute infection CXCR4 – T cells – T tropic or X4 strain – advanced disease |
|
HiV in fects ____ cells which migrate to regional ympohid tissues in ___ days and an increase in viral replication within __ days after exposure
|
CD4+ T cells, macs, DCs
3–5 days 14 days |
|
Best adaptive immune response to HIV is from _____. Antibodies are detectable within ___ after infection. Neutralizing ABs against gp120 develop ___ after infection and are/are not effetive.
|
CTLs
few weeks 2–3 months are not effective |
|
Most immunogenic HIV moelcules are ____.
Virus atttaches to DCs by ____ binding ____. |
gp120, gp40
DC–SIGN |
|
HIV is associated with hyper/hypo gammaglobuliemia due to ___
|
hyper
polylconal activation of B cels |
|
Phases of HIV
|
Acute HIV syndrome (spike in viral load and most of CD4 reduction)
Clinical latency AIDS |
|
Acute HIV syndrome
– clinical features |
– flu like sx x several weeks
– fever, HA, pharyngtisi rash, LAD, arthralgia, N/V/D |
|
AIDS
– clinical features |
CD<200 cells/mm3
AIDS defining conditions |
|
What is the singificance of the cCR5delta 32 mutation
|
homozygous – resistant to HIV infection
Heterozygous – nonprogressors (slow disease) |
|
ELISA for HIV
– sens/spec – false postive/negative profile– |
high sens, mod spec, good screen, requires confirm
False pos: autoimmune diz, multiple pregnancy, multiple blood transfusions, following immuization False neg: window period (up to 6 mo) |
|
Rapid HIV
– sens/spec – sample collection and timing |
high sens, mod spec
can detect HIV in blood/oral fluid <20 min turanround |
|
Western blot for HIV
– sens/spec – psoitive test = which bands – negative test followup |
high sens, high spec, but expensive
positive = 2/3 major bands (anti p24, gp41, gp160/120) neg ––> repeat WB in 4 weeks or WB for HIV2. if still neg ––> virologic testing |
|
HIV DNA by PCR
– sens/spec – detects what? – useful in __ |
mod sens, high spec
– detects HIV1 DNA in PBMC good for acute viral syndrome if antibody test is negative or for exposed infants |
|
HIV RNA PCR
– sens/spec – useful for __ |
mod sens, high spec
gives quantified viral load so good for therapeutic response and indication for treatment |
|
HIV p24 antigen
– useful for |
– neonates or makre of disease progression, but mostly replaced by PCR assays
– fourth generation HIV test (another screening that can detect infection sooner than eLISA) |
|
Management of HIV exposed infants
– testing – treatment |
– HIV 1 DNA PCR at birth, 2 w, 2 m, 4–6 m
– ELISA 12–18 mo to definitely exclude – umbilical cord samples have high false positive – PCP prophylaxis at 4–6 wk if infant infected until at least 1 year old |
|
Indications for HAART
|
all symptomatic people
asymptomatic if (CD4<350 definitely, 350–500 probably, >500 maybe). HIV RNA can influence decision to start |
|
Initial HAART therapy
|
nnRTI, PI or II + 2 NRTIs
|
|
HAART therapy: fusion inhibitors
– phase of inhibition / action – examples |
– viral binding/fusion/entry
– Maraviroc (binds CCR5) – Enfuvirtide (binds gp41) |
|
HAART therapy: Integrase inhiibitors
– phase of inhibition / action – examples |
– viral DNA integration
– Raltegravir |
|
HAART therapy: Nucleotide/nucleoside reverse transcriptase inhibitors
– phase of inhibition / action – examples |
– reverse transcriptase (incoporates into viral dna to terminate the strand)
– Zidovudine, didanosine, abacavir, tenofovir |
|
HAART therapy: nonnucleoside reverse transcriptase inhibitors
– phase of inhibition / action – examples |
– reverse transcriptase (binds RT and blocks it)
– efavirenz, nevirapine, delavirdine, etravirine |
|
HAART therapy: protease inhibitors
– phase of inhibition / action – examples |
– viral assembly, blocks protease
– ritonavir, indinavir, nelfinavir, lopinavir, atazanavir |
|
IRIS
– what is it – associated OIs – sx – risk factors – treatment |
– decline in clinical status (4–8 wk after HAART), reactivation of immune response to OIs when CD4 count rapidly increases
– OIs: TB, PJP, CMV, herpes, MAC – new/worse sx, fever, malaise, local rxn – risk: first HAART, CD4<50, recent OI tx – Supportive, NSAIDS/steroids |
|
Antibiotic prophylaxis: PJP
– indication – medications |
– CD4<200 OR CD4% <14, thrush, AIDS illness, FUO
– Bactrim, dapsone +/– pyrimethamine, atovquone |
|
Antibiotic prophylaxis: Toxoplasma gondii
– indication – medications |
– CD4<100 AND positive Toxoplasma IgG
– Bactrim, dapsone + pyrimethamine _ leucovorin, Atovaquone +/– pyrimethamine |
|
Antibiotic prophylaxis: Histoplasm capsulatum
– indication – medications |
– CD4<150 AND endemic area for histoplasmosis
– endemic areas = Ohio/MI river valley, Central/S america, Asia, Africa – ITraconazole |
|
Antibiotic prophylaxis: Coccidioides
– indication – medications |
– CD4<250 AND in endemic area AND positive IgM/G serologies
– endemic area = sonoran deser in arizona, entral valley in CA, New mexico, w Texas, Nevada, Utah – Fluconazole, itraconazole |
|
Antibiotic prophylaxis: MAC
– indication – medications |
– CD4<50
– Azithro, clarithro, rigabutin |
|
Sjogren's syndrome
– clinical features – autoantibody – treatment |
– xeropthalmia, xerostomia, sica sx, arthritis, interstitial nephritis, RTA, pulm involvement
– ANA, SS–A, SS–B, RF – Symptomatic (muscarinic agonists, csa drops, artificial tears), immunosuppressives |
|
Progressive systemic sclerosis or diffuse systemic sclerosis
– clinical features – autoantibody – treatment |
– fibrosis of skin, vasculopathy, hypertensive renal dz, interstitial lung dz, CREST sx
– ANA, SCL–70, anti endothelial ab, anticentromere (good prognosis) – ACEI for renal, immunosuppressive therapy |
|
Progressive sstemic sclreosis and limited (CREST)
– clinical features – autoantibody – treatment |
– calcinosis, raynaud's, esophageal motility, sclerodactyly, telangiectasia, pulm arterial hypertension
– anticentromere ab – CCB (for Raynaud's), PPI, metoclopromide, oral anticoagulation for pAH, endothelin receptor antagonist, postanoids, epoprostenol |
|
Polymyositis
– clinical features – autoantibody – treatment |
– idiopathic myositis, proximal weakness, incr CPK, aldolase
– ANA, Anti–Jo1, anti SRP and anti–PL7 (antithreonyl–tRNA synthetase) – steroids immunosuppressives (azathioprine, MTX) |
|
dermatomyositis
– clinical features – autoantibody – treatment |
– idiopathic myositis, prox muscle weakness, incr CPK/aldolase and DERM features (gottron's, heliotrope rash, mechanic hands), and malignancy association
– ANA, anti–JO1, antiPL–7, anti Mi2Ab (helicase) – steroids, immnosuppressives (azathioprine, mtx) |
|
Rheumatoid arthritis
– clinical features |
– f:m 3:1 4th/5th decade
– weakness fatigue prodrome – symmetric joints (MCP/MTP, PIP), joint effusions, restricted motion ––> joint deformities – rheumatoid nodules over bony prominences, splenomegaly, pericarditis, vasculitis, eye dz, renal amyloidosis |
|
Rheumatoid Arthritis
– diagnostic criteria |
RA score >=6:
Joints involved: 1 large (0), 2–10 large (1), 1–3 small (2), 4–10 small (3), >10 with 1 small (5) Serology: low pos RF or CCP (2), high pos RF or CCP (3) Sx duration: <6 wks 0, >=6 weeks 1 Acute phase reactants: abnormal crp and esr (1) |
|
Rheumatoid arthrtis
– immunologic features |
80% have incr RF (binds IgG Fc)
Incr ESR/CRP anti cyclic citrullinated peptide (anti CCP aka ACPA) as sensitive as RF but more specific |
|
Rheumatoid arthritis
– treatment |
– NSAIDS,
– steroids – intrasynovial joint injections – dMARDs – TNFa blocker, alpha–IL6R (tocilizumab), CTLA4ig (abatecept), anti cd20 mab (rituximab) |
|
JIA
– basic features – subtypes |
arthritis in <16 years old
– pauciarticular (most common) – polyarticular (1/3) – juveile spondylarthropathy – systemic onset Still's disease |
|
Pauciarticular JIA
– m:F, age – arthritis pattern – extraarticular pattern – labs – prognosis |
– 1:5, usu 18–36 mo
– mono or oligo articular, large – minmal (highest uveitis risk 20%) – neg RF, ANA+ – variable |
|
Polyarticular JIA
– m:F, age – arthritis pattern – extraarticular pattern – labs – prognosis |
1:4, usu 18–36 mo
symmetrical poly articular (>=5) some uveitis risk 15% RF+, half ANa+ variable (RF = more disability) |
|
Juvenile Spondyloarthropathy JIA
– m:F – arthritis pattern – extraarticular pattern – labs – prognosis |
4:1, late childhoo/teen
axial, sacroililtis, oligo/polyathritis ethesopathy, 20% uveitis, aortic insufficiency 90% HLAB27. neg RF chronic |
|
Systemic onset aka STill's JIA
– m:F – arthritis pattern – extraarticular pattern – labs – prognosis |
1:1, no peak
polyarticular fever, rash, LAD, myopericarditis, Kobner's phenomenon (salmon rash that triggered by touching skin) incr Ig (RF/ANA useuless), incr LFT/ESR/CRP/ferritin chronic arthritis 1/2, remission 1/4, severe 20% |
|
SLE
– diagnostic criteria |
4 of below (DOPAMINE RASH)
discoid rash, oral ulcers, photosensitivity, arthritis, malar rash, immune (anti DNA, anti Sm, anticardiolipin, lupus anticoag), Neurologic (sz, psychosis), renal (proteinuria >0.5 or 3+), ANA, Serositis, Heme (hem anemia, leukopenia<4000, lymphopenia <1500, plt<100k). |
|
Immunologic markers in SLE
|
ANA (very sens, lower spc)
anti dsDNA (very spec less sens, active dz and lupus nephritis) anti smith (very spec, less sens, ILD) Anti Ro (SS–A), also in Sjogren's, subacute cut lpus, neonatal lupus Anti histone drug induced lupus |
|
Sjogren's Syndrome
– types – symptoms |
primary (isolated autoimmune) secondary (comlication of RA, SLE, PM, scleroderma)
– xerostomia, xeropthalmia, parotid swelling, dry skin, purpura, urticaria, arthralgia, sinus infxn, obstructive airway, interstitial pneumonitis, dysphagia, CNS involvement – assoc w/ primary biliary cirrhosis, HIV, hepC |
|
Sjogren's ysndrome
– immunologic markers |
– RO/ SS–A, La/SS–B
– anti Ro (majority, anti La (40%) in primary SS – ANA +, RF+ 60–80% |
|
Polymyositis/Dermatomyositis/Inclusion body myositis
– symptoms |
heliotrope rash, rash on face, shawl sign, V shape, knees elbows
Gottron's papules photosensitivity Nail cracking, thickening, periungual telangiectasia Mechanic's hands 9fissured, hyperpig, scaly, (assoc c incr risk of interstitial lung dz) |
|
Inclusion body myositis
– how it differs from poly/dermatomyositis |
– more males than F
– CD8 T cell mediated (PM cell med, DM is Ab med/complement) – prox muscle weakenss that has distal spread, dysphagia – biopsy basophilic rimmed vacuoles and filamentous inclusions – possible viral association – older the age at sx onset, more rapid progression |
|
HLA that protect fetus from maternal immune rjeection
|
HLA G and F are expressed on the extra villous trophoblast
|
|
HLA gene is on chromosome
|
6
|
|
TRansplant organs that do not require immunosuppression
|
cornea, bone, joint
|
|
HLA matching – full versus extended match
|
full = 6/6 A, B, DRB1
10/10 adds C and DQ |
|
Best scid outcomes in which lymphocyte phenotype after transplant
|
T– B+ NK=
|
|
Examles of myeloablative regimens
|
– total body irradiation
– busulfan – etoposide – cytarabine – cyclophosphaimde – cytosine arabinoside – anti– CD45, antiCD66 anti CD20 |
|
Examples of nonmyeloablative regimen
|
– fludarabine
– cyclophosphamide – ATG – low dose total body irradiation – anti cd52 ab |
|
Examples of reduced intensity conditioning
|
low dose busulfan
low dose melphalan |
|
Effects of myeloabalative v.nonmyeloablative v. reduced intensity
|
Myeloablative – destroys host hematopoeitic cells
Nonmyelo – minimal cytopenia with significant lymphopenia Reduced – cytopenia |
|
Important cytokines in GVH reaction
|
IL–10, TNF a, IFNg
|
|
Acute v. Chronic GVH
– timing – cells – prophylaxis – treatment |
– 100 days
– CD45RO T cell and neutrophil V CD4T – Mtx, CSA, tacro steroids atg and T cell depletion v. t cell depletion – steroids, csa, tacro, atg, MMF, v. steroids, csa, thalidomide, ursodeoxycholic acid |
|
Acute v Chronic GVH
|
– macpap rash, diarrhea, abd pain, bloody diarrhea, ileus, cholestatic hyperbili, fever
– dyspig, alopecia, sclerosis, nail dystorphy, ulcers, sicca syndrome, fascciitis, myositis, contractures, weight loss, gi web/strictures, jaundice transaminitis, restr/obstr lung defects, BO, pericarditis, cytopenias |
|
Sinusoidal Obstruction Syndrome
– aka – associated with – diagnostic criteria |
aka hepatic sinusoidal veno occlusive disease
– conditioning therapy and drug tox (radiation, busulfan, csa, mtx, sirolimus) – Seattle (2 of 3 within 20 d of SCT: bili>2, hepatomeg/RUQ pain, >2% weight gain) – Baltimore (Bili>2 + 2 of 3: tender hepatomeg, >5% weight gain, ascites) |
|
Definitions of engraftment
– neutrophil – platelet |
3 days ANC >0.5 x 10^9 or 1 day of 1 x 10^9
plt >20 x 10^9 |
|
Methods of T cell depletion for SCT
|
– soy bean lectin and E rosetting
– E rosetting and CD34+ selection – monoclonal abs (CD3, CD2, CD6, CD25, CD52) |
|
Graves
– pathophys – clinical features – genetic assoc |
– Abs to TSH receptor. Mostly Th2 cells (also T and B)
– Hyperthyroidism (palp, tremor, heat intol, sweat, anxiety, emotional lability, wt loss), goiter, exopthalmos, pretibial myxedema – HLA–DR3, CTLA4 alleles |
|
Hashimoto's Thyroiditis
– pathophys – clinical features – genetic |
– Abs to PTO, thyroglobuline, TSH receptor. Lymph infiltration, Ig and complement fix, Hurthle (epith cells with eos–philic cytoplasm)
– atrophic thyroid or goiter. autoimmune thyroiditis. hypothyroid (fatigue, weak, cold intol, wt gain, constipation, dry skin, depr, growth failure) – HLA DR3, CTLA4 |
|
APS1 differs from APS2
|
– APS 1 doesn't involve DM or pituitary
– APS 2 is more common – APS 2 has no parathyroid or thyroid involvment – APS 1 usual develops in first 20 years, APS2 is 20–40 years. |
|
ALPS
– stands for – clinical sx – genetics – treatment |
– autoimmune lymphoproliferative syndrome
– LAD/splenomeg, DN T cells, apoptosis, incr IL–10, B12, IL–18, autoimmune cytopenias with hypergam, + fam hx – Type I (fas), Type Ib (FASL), Type IIa (caspas10) – immunosuppressives. BMT curative |
|
Autoantibody if Addison's disease develops and associated diseases
|
Ab to adrenal cortex enzyme 21 hydroxylase
– APS 1, APS2 (HLAb8, DR3) OR Autoab to cyp21A2 (makes cortisol) – primary adrenal failure (HLA DRB0404, DQ8, MICA 5.1) |
|
Diabetes Mellitus associated with autoabs to ____
– genetic HLA association |
– anti–GAD65, insulin, tyrosine phosphatase, zinc T8 transporter
– Genetics DR3, DQ2 and DR4, Dq8 |
|
Lymphocytic hypophysis
– what is it – associated abs |
inflammation of pituitary gland ––> fatigue, HA, visual field deficits
– anti–CTLA4 ab (ipilimumab) |
|
POEMS syndrome
|
polyneuropathy
organomegally endocrinopathies M protein skin (hyper pigmentation, hypertrichosis) |
|
Nephrotic syndrome
– symptoms |
> 3.5 g/ day proteinuria
edema hyperlipidemia hypoalbuminemia increased infections from low IgG secondary protein losses |
|
Nephrotic syndrome
– diseases |
Minimal change
membranous nephropathy focal segmental glomerulosclerosis |
|
Nephritic syndrome
– symptoms |
hematuria
edema hypertension |
|
Nephritic syndrome
– diseases |
Post strep GN
igA nephropathy Henoch schonlein purpura Membranoproliferative glomerulonephritis Rapidly progressive GN |
|
Minimal Change Nephrotic syndrome
– most common in – histo findings – treatment |
– chidlren
– nothing on light or IF. Bx = foot process effacement – prednisone |
|
Membranous Nephropathy
– most common in – associated with diseases – histo findings – treatment |
– adults
– Hep B, Malaria, syphilis, cancer, drugs, SLE, toxin – GBM thick with granular staining of IgG and C3 – controversial |
|
FSGS
– associated with diseases – histo findings – treatment |
– HIV, infxn, HTN, VUR, obesity, sickle, heroin
– glomerular collapse – prednisone, ACEIs |
|
Postinfectious glomerulnonephritis
– associated antigens – lab findings – treatment |
– NAPir (Nephritis associated plasmin receptor). SPEB (STrep pyogenic exotoxin B)
– low C3 with immune comlexes, cryoglobulins, RF, incr IgG. Dx based on prior strep infxn or positive ASO or anti–Dnase B –abx, supportive therapy |
|
Most common glomeruloneprhritsi in the world
|
IgA nephropathy
|
|
IgA nephropathy
– biopsy findings – treatment |
IgA staining of mesangium on IF. Elevated IgA complexes in serum
ACE/ARB for bp. prednisone if proteinuria. Occ statins |
|
HSP
–symptoms – biopsy findings |
– purpura, abdominal pain, arthralgias, hematuria (usu males, kids)
–IgA staining of mesangium on IF. Elevated IgA complexes in serum – treatment if renal dz with IVIG |
|
MPGN
– causes of secondary MPGN – treatment |
– essential mixed cryoglobulinemia (most common, assoc with HepC)
– – steroids if primary, and antiplt agents. Scondary ––> IFN alpha and ribarivirin (unless low clearance) |
|
RPGN
– biopy findings – most common cause of RPGN in adults – most common in children |
crescentic GN with focal necrotizing lesions in glomeruli
– pacuimmune GN – immune complex mediated GN |
|
Anti GMB disease
– can be limited to ___ or associated with ____ – biopsy findings – diagnosis |
RPGN or Goodpasture's
– crescents over >50% glomeruli with staining of IgG linear along GBM – abs a/ alpha 3 chain of type IV collagen, and often + pANCA and cANCA |
|
Pauci IMmune Crescentic GN
– secondary to _______ and associated with ____ meds – biopsy |
vasculitis, WEgner's, Microscopic polyangiitis, churg STrauss
Propylthiouracil, hydralazine, penicillamine, minocycline crescent shaped GN with focal lesions. 80% have + ANCA |
|
What key immunologic process causes MPGN
|
IgM immune complexes deposit on glomerular proteins, activate complement or via igM binding directly to glomerular proteins
|
|
Primary cause of Immune complex mediated RPGN and sx
|
Hemolytic uremic syndrome
– MAHA thrombocytopenia renal failure |
|
Autoantibodies to desmogleins 1 and 3 are in the _____ and cause ____
|
desmosome
pemphigus |
|
BP antigens 180 and 230 are in the ______ and autoantidobides cause ______
|
hemidesmosome/lamina lucida
pemphigoid and linear IgA bullous dermatosis |
|
Type VII collagen autoantibodies cause ____
|
epidermolysis bullosa acquisita
|
|
Ocular Cictricial pemphigoid
– wht is it – signs sx – dx – treatent |
– sight threatening chronic inflammation, scarring of conjunctiva ssoc w/ systemic pemphigoid
– conjunctival redness, mucus discharge, eyelid/eyelash in turning, breakdown of corneal/conj epith – biopsy – dapsone. severe dz steroids/cytotoxic therapy |
|
Peripheral Ulcerative Keratitis
– two types – signs/sx – treatment |
– (1) mild, both genders any age. (2) necrotizing (mooren's ulcer) vision threatening, adults unilat, bilat in AfAm men
– pain, photophobia, redness tearing. For necr ––> corneal distruction – mild topical abx/steroids. For necr ––> immunosuppression, surgery |
|
Episcleritis
– clinical features – treatment – optho emergency |
– superficial benign inflammation, usu women, 40s, conj redness for months/days, minimal pain
– cool compresses, tears, topical NSAIDS/steroids – no |
|
Scleritis
– clinical features –tx – optho emergency |
– sight threatening inflammation of sclera, usu women, 40s, 40% associ with RA. Ant eye redness, tearing, photophobia, pain c mvmt, decr vision
– NSAIDS, steroids, mtx, immunosuppressants – YEs |
|
Uveitis
– clinical features in the three types |
Ant: in front of lens, sudden pain, red, photophob, vision change, miosis. Tx :top steroid
Int: middle eye. bilateral blurry vision, floaters. Tx: periocular steroid Post: retina/choroid/vessels. Pain, redness, photphobia, vision loss. Tx: oral steroid/immunosup |
|
Autoimmune gastritis
– aka –most common cause of _______ – pathogenesis – associated with HLA ____ – dx – tx |
Pernicious anemia
Vitamin B12 deficiency auto abs to parietal cell and intrinsif factor (target H/K atpases) ––> lymph infiltration––> parietal cell atrophy ––> b12 malabsorptio HLA b8, DR3 low b12 and anemia/neuro sx. Schilling test b12 replacement |
|
Celiac
– sensitivity to ____ – associated with HLA___ – sx – biopsy |
–gliadin (wheat, barley, rye +/– oat)
– HLA DQ2 – diarrhea, flatulence, abd cramp, bloat, wt loss, fatigue, nutrional deficiency, anemia, osteoporosis – small bowel villous atrophy, resolves on gluten free diet. |
|
Celiac
– diagnosis – IF – associated with ___ |
– TTG IgA auto abs (but check IgA levelas well). IgA antigliadin abs have high sens but low spec. If IgA def ––> IGG anti ttg test
– granular IgA and complement at dermal/epidermal junction – dermatitis herpetiformis |
|
Typical EoE foods
|
milk, egg, wheat, soy
|
|
Autoimmune Hepatitis
– Type I auto abs – Type II auto abs |
type I (classic, most common)
– ANA, ss/dsDNA, saccharomyces cerevesiae, pANCA, smooth muscle, actin, soluble liver/pancreas ag type II – antiliver kidney micrsomes 1 (ALKM–1), liver cytosol antigen (ALC1 or LC1), rare ANA, +/– liver/pancreas ag, cyp2d6 |
|
Autoimmune Hepatitis
– assoc with HLA ____ – sx – lab – tx |
– DR3 early dz, DR4 late onset dz
– fatigue, jaundice, dark urine, abd pain, anorexia, amenorrhea, delayed menarche, HSM, spider nevi, cushingoid – AST/ALT elevation. Hypergammaglobulinemia (from auto abs) – tx steroids, immunosuppresives |
|
Primary Biliary Cirrhosis
– associated with HLA____ – immune pathophys – autoabs |
– A0201, DR8
– autoimmune attack on bile duct cells usu cd4/8 + T cells – antimitochondrial antibody |
|
Primary Sclerosing Cholangitis
– associated with ___ disease – associated with HLA__ – autoantibodies |
– ulcerative colitis
– HLA B8, DR3, DRw52 – anti smooth muscle antibodies |
|
Inflammatory Bowel disease
– typical genetic defect associated with Chron's – labs for UC and Crohn's |
– NOD2/CARD15 (crohn's and Blau's) and ATG16L1 (Crohn's)
– UC: ANCA+ and ASCA neg. – Crohn's: ANCAneg and ASCA pos |
|
Common IBD extraintestinal complications
|
– uveitis and episcleritis
– arthritis – liver sclerosing cholangitis |
|
IBD treatment
|
Anti TNF a antibodies (infliximab and adalimumab)
|
|
Multiple sclerosis
– pathogenesis – treatment – HLA associations |
– immune meditaed destruction of CNS myelin sheath by T cells. (Incr IL–12, IL–18, IFNg)
– steroids, IFNb, glatiramer, natalizumab (anti–VLA4 mab), fingoimod (sphingosine1PR) – HLA–DR2 |
|
Stiff Person syndrome
– auto antibodies – pathogenesis – tx |
– anti GAD (glutamic acid decarboxylase) and anti–amphyiphysin
– excessive firing or the motor unit – diazepam, IVIG, |
|
GBS/AIDP/AMAN/ASMAN
– auto antibodies |
anti GM1, GD1a, GD1b, GT1a, GaINAc–GD1a
|
|
Miller fisher syndrome auto antibodies
|
anti gq1b
|
|
CIDP auto antibodies
|
anti ganglioside (LM1, GM1)
|
|
Myasthenia gravis autoabs
|
antu AChR
|
|
Lambert Eaton syndrome auto antibodies
|
Anti– VGCC
|
|
Hyper eosinophilic syndromes
– eos threshhold – cause of morbidity and mortality |
– >1500/mm3
– cardiac disease |
|
hyper eosinophilic syndromes
– subtypes |
Myeloproliferative
Lymphocytic Familial |
|
Differential for hypereosinophilic syndromes
|
primary EGID
eosinophilic pneumonia churg– strauss syndrome systemic mastocytosis IBD adrenal insufficiency atheroembolic disease and HIV PID (ome's, HIES) |
|
Myeloproliferative HES variants
– |
FIP1L1/PDGFRA– associated HES (+ for that mutation, increased serum tryptase, most responsive to imatinib)
myeloproliferative with negative FIP1L1 mutation chronic eosinophilic leukemia |
|
Lymphocytic HES
|
clonal expansion of lymphocyte populations with aberrant phenotypes and skin manifestations (angioedema, urticaria, papules, modules)
– no response to imatinib |
|
Increased risk of ALL with these diseases
|
Down's
Wiskott Aldrich |
|
Increased risk fo AMl with these diseases
|
BLoom's syndrome
Down's congenital neutropenia Fanconi anemia |
|
Increased risk o CML with these_____
|
over expression of proto oncogen CLS2
13q deletions |
|
Hodgkin's lymphoma
– main cell type – associated with ____ infections |
Reed STernberg cell
HIV/EBV |
|
XLP associated with this lymphoma
|
Ileocecal B cell lymphoma
|
|
Burkitts' lymphoma
– associated infection – associated gene defect |
EBV
c–myc gen translocation at 8q24 |
|
Splenic marginal zone B cell lyphoma
– associated infection – associated gene defect |
HEp C
deletion 7q21–32 |
|
MALToma
– associated infection – associated gene defect |
– H pylori infection
– trisomy 3 or t (11, 18) |
|
Indications for SPEP
|
Unexplained anemia, back pain, weakness, fatigue
Osteopenia, osteolytic lesions, spontaneous fractures Renal insufficiency with bland urine sediment Heavy proteinuria in pt >40y Hyper Ca, hypergam, Ig deficiency Bence Jones proteinuria Unexplained peripheral neuropathy recurrent infections Elevated ESR or serum viscosity |
|
SPEP peaks (what fall under each type)
A–1 globulin A–2 globulin B1 B2 Between B and gamma Gamma |
–Alpha 1 antitrypsin, thyroid binding glubulin, –transcortin
–Haptoglobin, ceruloplasmin –transferrin –Beta lipoprotine, igGAM, complement –CRP, fibriniogen –Immunoglobulins |
|
MGUS SPEP indings and diagnostic criteria
|
< 3 g/DL of monoclonal paraprotein spike (gamma)
<10% BM involvement no myeloma related tissue impairment |
|
Symptoms of multiple myeloma
|
Calcium increase
renal failure anemia bone lesions (>3 g/dL mnoclonal parparotein spike, >10% clonal plasma cells on BM bx, myeloma impairment) |
|
Waldenstrom's Macroglobulinemia
– what is it – asssociated with these diseases – diagnosis |
– malignant prolif of B cells ––> incr igM ––> pallor, organomegaly, hyperviscosity, abnl coag, neuropathy
– HIV, Hep, autoabs, rickettsiosis – SPEP with M component with beta to gamma mobility |
|
Solitary Plasmacytoma
– dx |
monoclonal paraprotein spike on SPEP
lytic lesion on radiograph |
|
POEMS
– clinical features – diagnosis |
– 1+ of following: osteosclerotic myeloma!!, Castleman's disease !!, organomegaly, endocrinopathy (excl DM, thyroid), edema, skin changes, papilledema
– monoclonal parprotein spike on SPEP, with labmda chain on biopsy staining |
|
Castleman's disease
– clinical features |
giant cell lymph node hyperplasia
angiofollicular lymph node hyperplasia |
|
Heavy chain disease
– pathogenesis – most commonly reported – associated with autoimmune disease – rarest |
– secretion of incomplete Ig heavy chains b/c inability of heavy chain to form disulfide bonds with light chain
– alpha (severe diarrhea, wt loss from plasma cells) – gamma ( lymphoma like and 1/3 with RA, Sjogren's lupus, AHA) – mu (HSM, LAD, pallor) |
|
Which viral infection is associated with cryoglobulinemia and what types?
|
Hepatitis C virus (types II and III)
|
|
Cryoglobulinemia
– what is it – types |
single/mixed Ig that undergo reversible precipitation at low temps
– Type I: monoclonal Ig (M>G/A/light) – Type II: monoclonal RF (usu M with Fcs of IgG) – Type III: polyclonal RF |
|
Cryoglobulinemia
– presentation by type |
Type I: hyperviscosity & thrombosis: acrocyanosis, retinal hemorrhage, Raynaud's, livedo reticularis, purpura, art thrombosis)
Type II/ III: joint involvement, fatigue, myalgias, renal immune complex disease, cutaenous vasculitis, neuropathy |
|
Cryoglobulinemia
– diagnosis |
serum cryoglobulins (warm tubes without anticoags)
I precipitates in first 24 h III requires 7 days to precipitate |
|
Type I cryoglobulinemia is associated with ____
|
plasma cell dyscrasias
multiple myeloma |
|
Granulomatous diseases: Th1 dominated
|
TB
sarcoid Berylliosis Hypersensitivity pneumonitis Wegener's granulomatosis Tuberculoid leprosy |
|
Granulomatous diseases: Th2 dominated
|
Churg–STrauss syndrome
Lepromatous leprosy |
|
Granulomatous disease
– lab findings |
ACE (lacks disease specificity)
high vitamin D levels (1, 25(OH)2D3) osteopopntin TNFalpha |
|
What is Lofgren's syndrome
|
Triad: hilar adenopathy, acute polyarthritis, erythema nodosum
|
|
What is the key difference between sarcoid and hpyersensitivity pneumonitis in terms of T cell counts on BAL?
|
CD4/8 elevated in sarcoid, decreased in HP
|
|
Sarcoidosis
– PFT findings – types of granulomas – BAL findings – treatment |
– restrictive ( but occasionally mixed)
– perilymphatic noncaseating granulomas with CD4/8 T cells – elevated CD4 to 8 ratio – steroids, inflixiamb if refractory |
|
Berylliosis
– clinically similar to ___ – treatment |
sarcoidosis
removal from exposure to beryllium steroids |
|
WEgener's granulomatosis
– aka – clinical features – diagnosis – treatment |
– granulomatosis with polyangiitis
– affects small–medium blood vessels, granulomas in resp tract. Most have sinus, lung, kidney involvement (also skin/eye) – CANCA with PR3 specificity (occ pANCA) – prednisone + cyclophosphamide/rituximab. Aziothioprinee/MMF once controlled. mild dz ––> pred + MTX |
|
Histiocytosis X
– aka – most common sx – dx |
eosinophilic granuloma of the lugn
nonproductive cough lung biopsy, high res CT, cysts/nodules containing histiocytosis X cells of Langerhans origin with + CD1 and HLA–DR |
|
Clinical manifestations of amyloidosis
|
renal: protenuria, nephrotic syndrome
cardiac: cardiomyopathy hepatic: HSM neuro: peripheral nuropathy, stroke MS: macroglossia Heme: bleeding diathesis pulm: tracheobronchial infiltrates, pleural effusions, parenchymal nodules skin: waxy thickening, easy bruise, subcu nodules/plaques |
|
Primary amyloidosis
– deposits – associated with – dx –tx |
most common form
– Ig light chains – mutliple myeloma, Wasldenstrom's macro or non Hodgkin's lyhpoma – Ig in serum or monoclonal ight chains in urine – melphalan, prednisone, SCT |
|
Secondary amyloidosis
– associated with – dx – tx |
RA, IBD, periodic fever syndromes (FMF< FCAS< MWS)
Congo red deposits in tissue/fat pad biopsy resolve chronic inflammatory state (colchicine in FMF) |
|
Muckle Wells syndrome
– main features |
sensorineural deaness
recurrent hives intermittent fevers can have secondary amyloidosis with nephropathy trigger is cold temp mutation in NLRP3 |
|
Familial MEditerranean Fever
– main features |
common in Turkish/ Ashkenazi Jews
intermittent fevers serositis ––> abdominal pain/ pleuritis/ arthritis AA deposition (kidney, spleen liver, gut) tx with colchicine |
|
Mastocytosis:
type s of cutaneous` |
Urticaria Pigmentosa (discrete yellow–brown maculopapular/nodular with Darier)
Diffuse cutaneous mastocytosis (diffuse yellow brown thick skin, no lesions, usu <3 y) Mastocytoma of skin (solitary, self limted) Telangiectasia macularis eruptiva perstans (macular telangiectasias with incr mast cells at capillaries, usu adults) |
|
Systemic mastocytosis
– classification |
Indolent systemic masto (most common, good prog)
– sub: smoldering (>30% bm MCs, tryptase>200), isolated Bm masto (BM but no skin sx) Systemic masto c associated heme nonmast cell lineage (SMAHNMD) Aggressive systemic masto (hepatic fibrosis, portal HTN, malabsorption, cytopenia) Mast cell leukemia (rare, >10% immature Mc in peripheral) Mast cell sarcoma (tibia/skull) Extracutaneous mastocytoma |
|
Pathogenesis of mastocytosis
|
Activating mutations in ckit (KIT D816V0 ––> incr mast cells from constitutive activation of KIT tyr kinase signaling
stem cell factor is ligand for cKIT (CD117) and is required for mast cell survival |
|
Medications that can trigger mastocytosis
|
Alcohol, AmphoB
dextran, dextromethorphan IV VANc, quinine, polymyxin B alpha blocker, B blocker, opiods, Sux, atracurium, benzo/procaine ASA, NSAIDS |
|
Diagnostic criteria for cutaneous masto
|
at least one:
focal dense mast cell infiltrates (>15 MC/cluster) Diffuse mast cell infiltrates (>20 MC/hp) on skin bx cKIT D816V mut |
|
Mast cells are stained by ____
|
CD117 (c kit)
CD2 and or CD25 |
|
Mastocytosis symptoms
|
Cutaneous: UP, flushing pruritis
GI: Abd pain, N/V/D, peptic ulcer dz MS: Ms/bone pain, osteopenia/porosis, fracture CV: anphylaxis Neuropsych: decr attention, memory impairment, irritability |
|
Diagnosis of systemic mastocytosis
|
(1 major + 1 minor) OR 3 minor
Major: BX c mast cell clusters (>15MC) Minor: Bx c >25% MCs spindle/atyp shape C kit D816V mutation expression of CD2/CD25 on cD117+ MCs Total serum tryptase >20 |
|
Mast cell activation syndrome (MCAS)
– what is it |
pts with symptoms suggestive of mast cell activation but fail to meet WHO criteria
Monoclonal MC activation syndrome (MMAS) has presence of mutation but not full WHO criteria |
|
Mastocytosis treatment
|
Trigger avoidance (EtOH, NSAIDs, narc, exercise, stinging insect)
1st/2nd gen antihistamines and H2 blockers Disodium cromoglycate (GI sx) Epi Steroids topical (UP or DCM) Imatinib (masto without ckit mutation) DEXA scan and Ca supp for osteoporosis |
|
Pathophys o acute Hemolytic transfusion reactions
|
IgM Ab: RBC Ag comlexes ––> complement mediated lysis ––> coagulation cascade ––> cytokine release ––> fever/flank pain/hemoglobinuria ––> DIC/Shock
+ hemoglobinuria, elevated free Hgb, DAT |
|
Delayed hemolytic transfusion reactions are due to ___ antigens
|
Rh, Kell, Kidd, Duffy
+ LDH, bili, DAT |
|
Transfusion Related Acute Lung Injury (TRALI
|
resp distress 1–4 hours after transfusion (donor luekocyte antibodies directed to recipient neutrophi ag or HLA)
|
|
Warm Reactive AIHA
– what is it |
– polyclonal IgG against RBCs
|
|
Cold reactie AIHA
– what is it – associated with ____ |
– IgM binds I antigen (polysaccharide on RBCs) at temp <37 ––> complement activation
– mycoplasma, mono, elderly |
|
Paroxysmal cold hemoglobinuria
|
cold reacting biphasic anti–RBC IgG ab (Donath– Landsteiner Ab) against P antigen on RBC
|
|
Paroxysmal Nocturnal Hemoglobinuria
–what is it / abs– |
loss of PIG linkage proteins on rBC like CD59 and DAF
|
|
PPrimary autoimmune neutropenia
– affects ____ – clinical features – remission at ____ |
6–24 mo
– benign – minor infections (abscesses, URIs, OM) – 2–4 years |
|
Neonatal allo immune thrombocytopenia
– due to maternal abs against _____ – infant can develop _____ – treatment |
HPA–1 inherited fetal plt antigen from father
thrombocytopenia intracranial hemorrhage maternal plt transfusion |
|
ITP
– clinical sx – treatment |
– petechiaie, purpura, can develop intracranial hemorrhage
– IVIG if plt <20–30 |
|
Evan's syndrome
– development of ___ and ____ with positive ___ and no known etiology – associated with ____ immunodeficiencies |
ITP, AIHA
DAT CVID, ALPS |
|
TTP clinical features
– due to autoantibody to ___ |
fever
anemia (MAHA) thrombocytopenia renal failure neuro changes Auto ab to ADAMTS13 (VWF cleaving protease) |
|
Heparin Induced thrombocytopenia (HIT)
– mechanism – – can also happen with __ medicine or ____ |
IgG Fab binds comlex between heparin and platelet factor 4 ––> plt activation and consumption (less likely with LMW heparin)
quinine, RBC transfusion |
|
Three autoantibodies seen with SLE
|
anti Smit
Anti dsDNA anti U1 RNP |
|
Diagnostic criteria or ABPA in CF
|
acute/subacute clinical deterioration
IgE>2400 ng/ml specific IgE/SPT for A fumigatus precipitating or IgG abs for A fumigatus new CXR/CT findings bronchiectasis |
|
Newborn screening for CT tests for
|
immunoreactive trypsinogen (can be falsely psoitive)
|
|
Sweat chloride testing – lab values
|
elevated is >60 mEQ/L (borderline is 40–60)
|
|
Nasal polyps with CF ahve more _____ while NP with asthma have more _____
|
neutrophils
eosinpohils |
|
placental membranes expess HLAE, , G that interaction ____
|
LIRS (leukocyte inhibitory receptors) on Nk cells
|
|
Pregnancy uterus has decreased ___ cells and increased ____
|
T and B cells
NK and macrophages (prevent uterine infections) |
|
Sx o primary , secondary, tertiary syphilis
|
Primary: small painless chanchre (genitals, mouth, skin, rectum) resolves 3–6 wks
Secondary: skin rash on palms/soles, condylomata lata in genitals. Constiutional sx, LAD, vision change, hair loss Tertiary: CV syphiils (aortic aneurysm, valv dz), neurosyphilis, tumors of skin/bones/liver (gumma) |
|
Soluble agents produced by pregnant uterus
|
Progesterone (blocks TNF a and changes Th1/2 blance)
PGE2 (contributes to poor lypmp prolif) Th2 type cytokines (drive antibody mediated responses) Also Incr IL–10 producing T regs |
|
Which receptor allows transfer of maternal IgG cross the placenta and neonatal intestinal epithelium
|
FcRn receptor (IgG specific)
|
|
Treatment options or pregnant women with antiphospholipid syndrome
|
low dose aspirin
unfractionated heparin LMW heparin |
|
Types of antiphospholipid antibodies
|
anti cardiolipin
anti beta2 glycoprotein I lupus anticoagulant |
|
Diagnosis of lyme
|
– not useful if asx
– if symptomatic ––> ELISA/IFA to support dx, Western blot to confirm positive/indeterminate VIse (variable major protein like sequence expressed ELISA is as sens/spec as two tier testing PCR – low sens with lots of false positives |
|
Mechanisms to evade innate immunity used by TB
|
resistance to ROS (scavenging O intermediates by LAM (liparabinomannan); cyclopropanated mycolic acids in bact cell wall resist H2O2)
inhiibiton of phag–lyso fusion inhibition o phag acidification (by bacilli excluding ATPase) |
|
Important cytokine for preventing early TB infection
|
IFN gamma (activates macs) (and IL–12/IL–23)
|
|
Increased mycobacterial infections are associated with these PIDs
|
IL–12p40 / IL–12RB1/IL23b chain receptor def
IFNgR1/2 receptor def STAT–1 def CYBB mutation Hyper IgE (tyk2 def) NEMO mut IRF8 def |
|
Important cytokine for granuloma formation
|
TNFalpha
(explains why you can get reactivation of latent TB in people treated with infliximab or etanercept) |
|
Leprosy classifications and treatment
|
paucibacillary single lesion (lesions/nerves = 1)
– rifampin ofloxacin minocycline x 1 paucibacillary (2–5) – 12 mo of dpasone qd and rifampin q month multibacillary (>5) – 12 mo of dapsone, rifampicin, clofazimine |
|
HLA links for leprosy
|
HLADR3 for PB
HLA dq1 for MB |
|
Type II or Erythema Nodosum leprosum
– what is it – sx |
– immune complex disorder often seen during treatment of MB/BT leprosy
– fever, tender nodules, neuritis, edema, arthralgias, leukocytosis, iridocyclitis, pretibial perisotitis, orchtitis, nephritis – |
|
Diagnosing Hep A virus infection
|
Serologic (IgM HAV abs at onset –4–6 mo; IgG in early convalescence to decades)
Can also use RNA |
|
Diagnosis of HBV
|
RIA/EIA for serum hepatitis B surface antigen (1–10 wks ater exposure to 4–6 mo)
After 6 mo – chronic infection ––> hep B surface Ab During windo period, can dx using IgM to core ag |
|
I chronic HBV infection need to monitor for _____
|
liver disease
HBV DNA titers and ALt levels |
|
Abs/Ag in HBV carrier and vaccinated
|
Carrier: undetectable HbeAg, normal ALt, undetectable HBV DNA
Vaccinated: Only HbsAB |
|
Hep C diagnosis
|
serologic assays for Abs
HCV RNA assaysR |
|
outine testing for HCV recommeded i ____
|
illegal IV drug use
Rec'd clotting factors before 1987 Received blood/tranplant before 1992 received chroni hemodialysis HIV Children born o mothers with HCV |
|
Hep C EVR (early virologic reponse)
– defined – prognosis |
– 2 log decline in HCV RNA from baseline to week 12 of treatment (if not, failure o therapy)
– rapid virological response = undetectable HCV RNA by week 4 ––> predictive of sustained virologic response |
|
Diagnosis of syphilis
|
– initial non specific nontreponemal antibody test (VDRL, RPR, TRUST, all semiquantitative)
– ollowed by specific treponemal test (FTA abs, MHA tp (microhemagllutination tes tfor abs to treponema), TP–PA (particle agglutination assay) TP–EIA (most favored |
|
Asymptomatic person with reactive nontreponemal and treponemal tests =
|
Latent syphilis
|
|
Diagnosis of new infection in patient with history of syphilis
|
quantitative testing on RPR showing four fold or greater increase in antibody titer
|
|
False positive non treponemal tests associated with
|
pregnacy
IV drug use TB/ rickettsial non syphilis treponemal endocarditis HIV infection |
|
Allergens and their abbreviations
dust mite cat dog cockroach |
der p1, der f1
fel d 1 can f 1 bla g1–4, Per a 1 |
|
Changes associated with allergen immunotherapy
– Abs – receptors –basophils – cytokines |
– Incr IgG1 and 4, incr then decr allergen–specific IgE, incr IgA in resp secretions
– incr T regs and % CD8+ t cels – decr low afinity FceRI and FceRII (CD23) – decr basophil hypereactivity – shift from IL 4/5/13 to IFN g/TGFb/IL–10 |
|
AIT:
Conversion from Volume/volume ratio to weight/volume ration is ____ fold order f vials from least conc to maint conc |
100
silver, green, blue, yellow, red |
|
Proteolytic enzymes in AIT
– which extracts have them – which can they be mixed with |
– cock roach and mold (mix with only each other and dust mite)
– dustmite in 50% glycerin is safe to mix with pollen, dog, cat, cockraoch, and mold – ragweed and cat in 50% glycerin resist degradation when mixed with high protease extracts |
|
Weed cross reactivity
|
– short/giant/false/western ragweed (ambrosia)–
– sage/wormwood/mugwort (artemisia) – thistle/lambs quarter/burning bush (chenopod) – pigweed / red root pigweed (amaranthus) – salt bush / wingscale (atriplex) |
|
Grass cross reactivity
|
– medow fescue / timothy / rye /Kentucky bue / orchard / red top (Festuca)
|
|
Cross reactivity of trees
|
– juniper / cedar / cypress (cupressaceae)
– birch /alder / hazel /hornbeam (betulaceae) – oak / beech /chestnut (fagaceae) – ash / olive / privent (oleaceae) – cottonwood / poplar / aspen (populus) |
|
which allergen extracts are standardized
|
Grass (northern grases and bermuda)
ragweed cat dustmite |
|
AIT effective maintenance dosese are ____
|
5– 20 mcg per 0.5mL maint dose
|
|
Systemic reaction rate with AIT is
|
1/2000 injections
(greater fatal risk of on beta blocker) Fatal reaction in 1 in 2.5 million |
|
Probably effective maitenance dose for
grass short ragweed cat dog dustmite bermuda |
1000–4000 BAU
1000–4000 AU 1000–4000 BAU (1:10–1:100 w/v, 15 mcg) 500–2000 AU 300–1500 BAU |
|
Systemic reaction risk factors for AIT
|
beta blockers
durng priming of pollen season during buildup during accelerated or rushed protocols first injection from new vials unstable asthma dosing error history of previous systemic reaction |
|
Relative contraindications to immunotherapy
|
pregnancy (ok to continue without increasing dose if patiet pregnant after starting)
serious immunodeficiency malignancy uncontrolled asthma cardiovascular disease children < 5 years systemic mastocytosis |
|
histamine receptor types: H1
– receptor expression – general function – CNS function |
– widespread (nerve, airway/vessel smooth muscle, epith/endoth, immune cell, hepatocytes)
– Incr pruritis, vasodilation, hypoTN, tachycardia, BRONCHOCONSTR, COUGH receptor stim, decr AV node conduction time – sleep/wake, food intake, temp reg, memory |
|
histamine receptor types: H2
– receptor expression – general function – CNS function |
– widespread (same as H1 but NOT MACS)
– GASTRIC ACID secretion, vasc permeability, hypoTN, flushing, tachycardia, BRONCHODIL, AIRWAY MUCUS –neuroendocrine |
|
histamine receptor types: H3
– receptor expression – general function – CNS function |
– histaminergeic neurons, eos, DCs, monos
– pruritis, congestion. (PREVENT EXCESSIVE BRONCHOCONSTR) – decr histmaine/dopa/serotonin/norepi/Ach release |
|
histamine receptor types: H4
– receptor expression – general function – CNS function |
– bone marrow, HSCT, eos, neut, C, TC baso, mast
– incr prutitis, congestion, diff of myeloblasts – unknown |
|
H1 antihistamine effects
– anitallergic –antiinflammatory |
antiallergic: inhibit Mc/baso mediator release
antiinflam: inhibit cell adhesion moelcule expr and eosinophil chemotaxis |
|
Histamine is metabolized by 2 major pathways
|
(1) histmaine N methyl trasnferase
(2) diamine oxidase |
|
Fastest onset of the antihistamines
– 1st gen – 2nd gen – topical |
– epinastine (0.1 hr)
– diphenhydramine = benadryl = doxepin = hydroxyzine (2h) – cetirizine = levocetirizine (1h) |
|
Slowest onset of the antihistamines
– 1st gen – 2nd gen – topical |
– chlorpheniramine (3h)
– desloratadine/allegra (2h) – azelastine (0.5 h) |
|
Shortest halflife of the antihistamines
– 1st gen – 2nd gen – topical |
– benadryl
– cetirizine – epinastine |
|
Longest halflife of the antihistamines
– 1st gen – 2nd gen – topical |
– chlorpheniramine
– desloratidine – levocabastine |
|
When to dose adjust for antihistamines for hepatic/renal impairment
|
first gen antihistamines – for hepatic impairment
2nd gen antihistamines – for both renal and hepatic (usually) |
|
AEs with anithistamines
|
– CNS (first gen penetrate BBB)
– cardiac (first gen cause prolonged QT) – H1: incr sedation/appetite, decr cog, decr CNS neurotransmission – Muscarinic: dry mouth, urinary retention, sinus tachy – alphaadrenergic: hypoTN, dizzy, reflex tachy – serotonin: incr appetite – ion channels: prolonged QT |
|
Second generation antihistamine that is safe in pregnancy
|
cetirizine and loratadine
|
|
Longest half life among the following:
loratadine cetirizine fexofenadine hydroxyzine |
hydroxyzine (20h)
(fexofenadine – 14h, cetirizine – 10h, loratadine 8h) |
|
Theophylline inhibits ____ resulting in ____ and is a ____ antagonist
|
phosphodiesterase
cAMP adenosine antagonist |
|
THerapeutic range for theophylline
|
5–15 mg/L
check level after 3 days o maximum dose |
|
Theophylline adverse efects
– most common – most serious |
– headache, nausea, vomiting, abdominal discomfort, restlessness
– gastric acid secretion/reflux/diuresis – convulsions, cardiac arrhythmias, death AEs usually occur at plasma levels >20 mg/L |
|
Factors that decrease theophylline clearance (incr serum level)
|
macrolid
cimetidine (not ranitidine) cipro verapamil zileuton allopurinol high carb diet CHF/ liver dz/ viral infection/ old age |
|
FActors that increase theophylline clearance (decrease serum level)
|
carabazmepine, phenobarb, phenytoin
rifampin ethanol smoking tobacco/ marijuana high protein and low carb diet younger chidlre metabolize more than older |
|
Mechanism of beta agonists
|
bind GPCR and activate adenylyl cyclase ––> incr cAMP ––> activate protein kinase A ––> plation and muscle relaxation
|
|
Types of beta agonistis
|
– b1: heart
– b2 lung and inflammatory cells – b3: adipose tissue |
|
Non bronchodilator actions of beta agonists
|
– incr mucociliary clearance
– protect epithelium a/bacteria – suppress microvascular permatbility – inhibit cholinergic tansmission |
|
Short acting beta 2 agonists
i– ex – onset of actio – duration of action |
albuterol, terbutaline pirbuterol, levalbuterol
2–4 min 4–6 hrs |
|
Long acting beta agonisits
– example – onset of action – duration of action |
formoterol, salmeterol
formoterol (2–3 min), salmeterol (30) >12 h |
|
ultra long acting beta agonists
– exmaples – onset of action – duration of action |
carmoterol, indcaterol
< 5 min >24 hr |
|
Adverse efects of beta agonists
|
tremor
tachycardia prolonged QTc / arrhythmias hyperglycemia, hypokalemia, hypomagnesemia transient incr hypoxia |
|
Cardioselective beta blockers
– examples – affect on bronchoconstriction |
metoprolol, atenolol
greater afinity for beta 1 receptors and less risk of bronchoconstriction or loss of asthma control |
|
Arachidonic acid pathway
– ___ converts AA to _____ (3 pathways) which turn into ____ – ____ convert LTA4 to _____ (2) – ___ forms ____ (5) |
(1) 15–LO, 15–HPETE, lipoxins
(2) 5–LO, 5HPETE, LTA4 (3) COX1/2, PGG2, PGH2 – LTA4 hydrolase/LTB4; LTC4 synthase / LTC4/LTD4/LTE4 – PGH2 into TXA2, PGD2, PGE2, PGF2, PGI2 |
|
Leukotriene receptors
– function – receptor affinity |
CysLT1R: bronchoconstriciton, mucus secretion, vascular permeability.
– LTD4>LTC4>LTE4 CysLT1R: edema formation, endothelial activation (NO bronchoconstriction) – LTC4=LTD4>LTE4 |
|
Leukotriene receptor antagonists
– target – examples |
cysLT1 receptor only
montelukast, pranlukast, zafirlukast |
|
Leukotriene receptor antagonists
– clinical uses |
– exercise induced bronchospasm
– allergic asthma/allergic rhinitis – AERD (help both early and late phase respons) – prior to aspirin desens – antiinflammatory (decr eos, decr eNO, decr bronchial hyperreactivity – |
|
Adverse effects of leukotriene receptor antagonists
|
– elevated transaminases
– anaphylaxis, AE, dizzy dyspepsia, muscle weakness – suicidal thinking or behavioral changes – interacts with warfarin ––> incr PT – preg class B |
|
Zileuton
– function – preg class – AEs – avoid if ___ – affects clearance of ____ |
5–LO inhibitor, good for asthma
preg class C AEs: elevated LFTS! headache, dyspepsia myalgias, leukopenia avoid if liver disease or EtOH consumption decr clearance of theophylline, warfarin, propanolol |
|
LTB4 is a chemoattractant for ___
|
Neutrophils, eosinophils
|
|
Mast cell stabilizers: mechanism
|
blocks IgE mediated calcium channel activation and blocks cl channels (lower intracellular ca levels) prevents mast cell release of histamine/LTs; eo/neut activation
|
|
Acetylcholine receptor types
|
Muscarinic receptors (GPCRs). (1) M1 on eos from COPD sputum (2) inhibitory receptor on parasympathetic nerves (3) primary mediator of smooth muscle contraction, most in bronchi
|
|
Anticholinergic drugs
|
Atropine, Ipratropium bromide, tiotropium bromide
|
|
Ipratropium and Titropium (blocks which receptor)
|
both block M2 and M3 (ipratroprium can have paradoxical bronchoconstriction)
|
|
Allergic response (which agents affect which stage : mast cells stabilizers, anticholinergics, corticosteroids)
|
MC stab =both. antichol = both. steroids = late not early.
|
|
Mechanism of corticosteroids
|
bind glucocorticoid receptor, heat shock proteins dissociated and steroid/receptor translocate into nucleus gene activation and repression, interfere with NFkB, recruit histone deacetylasess, induce TF inhibitors of NFkb (FILZ, IIkkBa)
|
|
Effects of oral steroids
|
decr t and B cells, decr CD4 more than 8, upregulates CXCR4, decr IgG/M, incr neut. decr eos/basos/monos, spares innate immunity
|
|
AEs of steroids
|
STEROID (stunt growth, subcapsular post cataracts, steroid myopathy, Thrush, Eyes: incr IOP, cataracts, glaucoma, Endocrinediabetes, Rage(psych and incr BP), Osteopenia/porosis/obesity, Immunosuppression and Increased wt, Dysphonia, diabetes, derm)
|
|
Medications that decrease glucocorticoid metabolism
|
Ketoconazole, OCPs, macrolides
|
|
Omalizumab binds this
|
CH3 domain (FC portion of IgE molecule)
|
|
Omalizumab decreases these
|
free serum igE and eos, expression of FceRI on effector cells, circulating IL–13 and FeNO, mediator release from mast cells and basos, B cells
|
|
IgE binds to this portion of the FceRI
|
alpha chain
|
|
AEs associated with omalizumab
|
local reaction at the injection site, URI, headache. Anaphylaxis (0.2% incidence) can be within 2 h or delayed
|
|
Abatecept (orencia): target, molecular structure, indication
|
B7–1/B7–2 (CD80/86), CTLA4– IgG1 fusion protein, RA and JRA
|
|
Alefacept (amevive): target, structure, indication
|
CD2, LFA3–IGG1 Fc fusion protein, plaque psoriasis
|
|
Methotrexate (use, immune effect, AEs)
|
RA and autoimmune dz; inhibits cell replication ; teratogen, oral ulcers, nausea, diarrhea arthralgia, fatigue, LFTs, incr infxn
|
|
Azathioprine (imuran/azasan: use, immune effect, AEs)
|
severe AD; inhibits purine nucleotide synthesis, myelosuppression, GIsx, hepatotoxicity, infections, skin cancer
|
|
Mycophenolate Mofetil (CEllcept: use, immune effect, AEs)
|
severe AD, organ txpt; affects purine nucleotide synthesis; diarrhea, vomiting, livertox, myelosuppresiion, incr infections
|
|
CSA and tacro function by binding which proteins
|
immunophilins (CSA binds cyclophilin and tacro binds FK binding protein)
|
|
AEs of calcineurin inhibitors
|
nephrotox, HTN, HA, hypertrichosis, gingival hypertrophy
|
|
Types of DNA based therapies
|
DNA vaccines, CpG DNA therapy(ragweed IT), oligodeoxynucleotide (antisense GATA3), siRNA (Vitravene for CMV retinitis)
|
|
Uses for IVIG (immune, autoimmune, neuro, infectin, other)
|
PID; ITP/Graves opthal; CIDP/GBS, multifocal motor neuropathy; CMV pneumonitis; Kawasaki’s
|
|
Probably beneficial uses for IVIG (immune, autoimmune, neuro, infectin, other)
|
Peds HIV, B cell CLL, specific ab def ; dermato/polymyositis, autoimmune uveitis; MGravis, Lambert–Eaton syndrome; neonatal sepsis, TSS, rotaviral enterocolitis; TEN SJS;
|
|
Processing of IVIG
|
Isolation by modified Cohn Oncley cold ethanol fractionation for bact/prions; filtration for abs and viruses; stabilization to prevent aggregation ; viral inactivation;
|
|
IVIG dosing and SCIG dosing
|
400–600 mg/kg every 3–4 weeks. 100 mg/kg/week
|
|
IVIG not indicated for the following
|
selective igA def, IgG d/t protein loss, IgG subclass def, transient hypogam of infancy
|
|
IVIG acts by the following mechanism
|
Fc receptor blockade (cd16 on NK, CD32 on B cll, Fc receptors on phagocytic cells)
|
|
Common and serious IVIG reactions
|
headache, fever, fatigue, chills, N/V, myalgias (usu rate dpdt). Injection site reactions for SCIG. Aseptic meningitis, Anaphylaxis (esp if IgA def), acute renal failure, thrombotic events, hemolytic anemia, TRALI
|
|
Cause of renal insufficiency when treating patients with IVIG
|
sucrose hyperosmolar renal damage
|
|
Inteferon therapy ( mechanism)
|
activates JAK/STAT pathways leading to antiviral/antiprolif effects
|
|
IFN alpha AEs
|
fever, flu like sx, cytopenias, liver dysfxn, neuropsych sx, cerebrovascular events, hypersens, GI bleed, hyperglyc, pulm d/o, eye d/o, pancreatitis, peripheral neuropathy
|
|
IFN alpha precautions
|
careful if cardiovascular dz, thyroid dysfunction, coagulation defect, or severe myelosuppression. Should have periodic eye exams
|
|
Recombinant IFN alpha 2a indication
|
chronic Hep C, hairy cell leukemia, CML (pegylated for Hep B/C)
|
|
Recombinant IFN alpha 2b indication
|
hairy cell leukemia, kaposi’s sarcoma, chronic hep B/C, malignant melanoma, follicular lymphoma, condylomata acuminate, (pegylated for Hep C)
|
|
IFN alpha con–1 indication
|
Hep C
|
|
IFN alpha n3 leukocyte derived
|
HPV genital warts
|
|
IFN beta 1a and 1b indication
|
relapsing multiple sclerosis (1 b for early MS)
|
|
Bioengineered IFN gamma 1b indication
|
CGD and malignant osteopetrosis
|
|
Recombinant IL–2 indication
|
metastatic renal cell carcinoma and metastatic melanoma
|
|
IFN beta and gamma precautions
|
caution if seizure disorder or cardiac disease (myelopsuppressio for IFN gamma, watch for autoimmune in IFN b)
|
|
Recombinant IL–2 AEs /precautions
|
hypotension, diarrhea, oliguria, chills, vomiting, cytopenia, blackbox for capillary leak syndrome, coma. D/c if pts develop lethargy/somnolence. Should have normal cardiac/pulm/hpatic/CNS function at start
|
|
Recombinant IL–11 precautions/ AES
|
vomiting, edema, fever, hypersen, CV abnl, pleural effusion, papilledema. Watch for anemia, incr tox after myeloablation
|
|
Inteferon therapy ( mechanism)
|
activates JAK/STAT pathways leading to antiviral/antiprolif effects
|
|
IFN alpha AEs
|
fever, flu like sx, cytopenias, liver dysfxn, neuropsych sx, cerebrovascular events, hypersens, GI bleed, hyperglyc, pulm d/o, eye d/o, pancreatitis, peripheral neuropathy
|
|
IFN alpha precautions
|
careful if cardiovascular dz, thyroid dysfunction, coagulation defect, or severe myelosuppression. Should have periodic eye exams
|
|
Recombinant IFN alpha 2a indication
|
chronic Hep C, hairy cell leukemia, CML (pegylated for Hep B/C)
|
|
Recombinant IFN alpha 2b indication
|
hairy cell leukemia, kaposi’s sarcoma, chronic hep B/C, malignant melanoma, follicular lymphoma, condylomata acuminate, (pegylated for Hep C)
|
|
IFN alpha con–1 indication
|
Hep C
|
|
IFN alpha n3 leukocyte derived
|
HPV genital warts
|
|
IFN beta 1a and 1b indication
|
relapsing multiple sclerosis (1 b for early MS)
|
|
Bioengineered IFN gamma 1b indication
|
CGD and malignant osteopetrosis
|
|
Recombinant IL–2 indication
|
metastatic renal cell carcinoma and metastatic melanoma
|
|
IFN beta and gamma precautions
|
caution if seizure disorder or cardiac disease (myelopsuppressio for IFN gamma, watch for autoimmune in IFN b)
|
|
Recombinant IL–2 AEs /precautions
|
hypotension, diarrhea, oliguria, chills, vomiting, cytopenia, blackbox for capillary leak syndrome, coma. D/c if pts develop lethargy/somnolence. Should have normal cardiac/pulm/hpatic/CNS function at start
|
|
Recombinant IL–11 precautions/ AES
|
vomiting, edema, fever, hypersen, CV abnl, pleural effusion, papilledema. Watch for anemia, incr tox after myeloablation
|
|
Recombinant Il–11 indications
|
chemotherapy induced thromboctyopenia
|
|
REquirements of an aeroallergen (from Thommen's posulates)
|
1. buoyant
2. allergenic 3. Present in a significant concetration |
|
Sampling aeroallergens
– type methods – two types of samplers |
– sedimentation v. gravitational sampling
– Durham Sampler and Settle Plates |
|
Pros and Cons of Durham Sampler
|
– microslides coated with adhesive and exposed x 24h
– low cost, durable, power indepedent – biased toward larger particles, cannot determine air [] |
|
Procs and Cons of Settle Plates
|
– particles are allowed to settle on agar and incibuted/examined/counted
– identifies airborne organisms – biased toward larger particles, cant determine air []. good for indoor use only |
|
Rotorod
– pros and cons |
– rod sweeps through air and coated with adhesive
– not effecient for small particles – not affected by wind, good for most airborne paticle and allows for calculation of [] |
|
Burkard Spore trap
–pros and cons |
– known air drawn in through a sampling orifice with a tale to keep oriented
– more efficient than the rotorod for particle collection < 10 micron, consistent flow speed with samples over varying time frames – more expensive and affected by wind speedA |
|
nderson Sieve IMpinger (Multistage Cascade Samler)
|
Series of sieves with air passing though
– separates particles by size, good for brief collection periods and culture based sampling of airborne fungi – expensive |
|
Allergenco air sampler
|
suction sampler that collects on lab slides, usu for indoor use
– |
|
Appearance of grass pollen and size
|
large (20–45 micron) round pollen grain with thickened ring and may have a cap (operculum)
|
|
Three main allergenic southern grasses
|
Bermuda
Bahia Johnson (also lovegrass, prarie rass, corn, sugarcane) |
|
Main Northern grasses
|
Timothy
Orchard Rye Fescue Bluegrass Other(redgrass, sweet vernal, brome, velvet, canary) |
|
Grass cross reactivity
|
Bermuda, love grass, prarie grasses
Bahia, Johnson, corn, sugarcanes Northern grasses |
|
Chenopod
– cross reactivity – appearance / size – types |
– chenopods and amaranths (pigweed or careless, w water hemp)
– golf ball (20–35 micron) – lambsquarter, wingscale/saltbush, burning bush, russian thistle |
|
RAgweed (ambrosia)
– appearance / size – types – pollen food asociations |
– spiky golfballs, 15–25 microns
– giant, short, western, false ragweed – banana, cantaloupe, watermelon season ends with first frost |
|
Sage and Mugwort
– appearance / size – types – pollen food associations |
– round with three bubbles (20–30 micron)
– no other names – celery spice, peach, mustard |
|
Cockleburs (Xanthium)
– appearance/size– |
blunted spikes, similar to ragweed but larger in size and blunter spikes
|
|
Nettle
– types – apperance |
stinging nettle (N America) and wall pellitory
smallest pollen with 3–4 pores (round with weird polygons in the middle) |
|
Plantain
– appearance |
large 20–40 micron and periporate (6–10 pores) with a pore cap that gives donut appearance
|
|
Dock or Sorrel
– types – apperance / size |
curly dock and sheep sorrel
round with inclusion granules (speckled) |
|
Tree pollen
– pollination time and exceptions |
Mostly spring
Fall: elm Mid winter: mountain cedar |
|
Ash family
– examples – location – pollen appearance |
ash, olive, privet, russian olive
Ash (east/central N america); Olive (Western N am, europe) Square/pentagon appearance with furrows (olive/privet have three furrows) |
|
Birch family |
birch, alder, hazelnut, hornbeam |